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Abstract
G protein-coupled receptors (GPCRs), the largest family of membrane proteins on the cell surface, play
essential roles in signal transduction in all eukaryotic organisms. These proteins are responsible for
sensing and detecting a wide range of extracellular stimuli and translating them to intracellular responses.
This signaling requires a tight control for receptor activation without which abnormal signal leads to
diseases. In fact, malfunctions of these receptors are associated with numerous pathological conditions
and currently an estimated 40-50% of therapeutic drugs are designed to target these receptors suggesting
that further increases in understanding of GPCRs and the signaling pathways they initiate will lead to new
and more specific drug targets. We have used Saccharomyces cerevisiae GPCR Ste2p as a model system
to understand structure-function relationships of these receptors. In this study, the role of the extracellular
N-terminus has been examined using various biophysical methods with the anticipation to uncover its role
in receptor function. It was found that some residues in the extracellular N-terminus were not accessible
to a sulfhydryl reagent and that the alternating pattern of accessibility is consistent with the structure of a
beta strand. This beta strand was found to be involved in dimer formation. Moreover, a conserved
tyrosine residue in the middle of the beta strand was found to interact with two residues in the
extracellular loop 1. It was also found that the N-terminus is involved in negative regulation and
important for cell surface expression.
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Chapter 1
General introduction
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G protein-coupled receptors: an overview
Signal transduction is an essential biological process that is required to maintain cellular
homeostasis and coordinated cellular activity in all organisms. The membrane proteins at the cell
surface play crucial roles in these fundamental processes of communicating between the external
and internal environment of the cell. The largest and most diverse membrane protein family on
the cell surface is the G protein-coupled receptors (GPCRs) that are involved in nearly all
important physiological processes in eukaryotic organisms (1). These proteins function by
sensing an astonishing variety of extracellular signals, including photons, protons, ions, odorants,
amino acids, nucleotides, steroids, fatty acids, proteins and peptides (2).
The GPCR family of proteins comprises approximately 4% of the encoded human genes
corresponding to over 800 members (1,3-5). Modifications in the signaling of these receptors are
pertinent for many pathological conditions including cardiovascular and pulmonary diseases,
pain perception, obesity, cancer, and neurological disorders (1,6,7). In fact, GPCRs are
considered one of the most successful therapeutic targets with more than 25% of all modern
prescription drugs targeting these receptors (8-12). However, only a very small fraction of the
known GPCRs are therapeutic targets. Many GPCRs remain ‘orphan’, which have not been
assigned either ligands and/or functions. Even for many receptors whose ligands are known,
there is a need for identifying alternate agonist and antagonist ligands. Regarding these facts, it is
suggested that GPCRs will continue to be important drug targets of the future (1,13-15). Thus,
the studies of GPCRs will contribute significantly to the understanding and treatment of a variety
of diseases.
GPCRs share a common structural organization with an extracellular N-terminus, seven
transmembrane domains connected by extracellular and intracellular loops, and a cytoplasmic C2

terminus (16-18). Despite the astounding diversity of their ligands, biological function and lack
of strong sequence similarity, all GPCRs share common mechanisms of signal transduction. i.e.,
they couple the binding of ligands to the activation of specific heterotrimeric guanine nucleotidebinding proteins (G proteins) and/or non-G protein mediated signaling, leading to the modulation
of downstream effector proteins and gene expression (19-22).

Figure 1.1. Cartoon of a GPCR showing the seven transmembrane domains connected by
alternating extracellular and intracellular loops. Agonist-binding activates the receptor
triggering the exchange of GDP by GTP at the Gα subunit of the heterotrimeric G protein.
This results in dissociation of the Gβγ from the Gα. Both GTP-bound Gα and the released
GβƔ can mediate the stimulation or inhibition of intracellular effector proteins. (Taken
from (23))
Upon ligand binding, the receptor induces a conformational change in the intracellular
heterotrimeric G proteins that act as molecular switch leading to intracellular responses. The G
proteins are composed of three subunits (α, βγ dimer). For many GPCRs, activation leads to
exchange of GDP by GTP on the Gα-subunit triggering the dissociation of the α-subunit from the
receptor and the βγ dimer (24). Both the GTP bound α-subunit and the released βγ-dimer can
3

mediate the stimulation or inhibition of effector proteins such as enzymes and ion channels [e.g,
adenylate cyclase, guanylyl cyclase, phospholipase C, mitogen-activated protein kinases
(MAPKs), Ca+2, and K+ channels]. Thus, stimulation of GPCRs with specific agonists results in
changes in the concentration of second-messenger molecules (24). However, this general
mechanism of signal transduction by GPCRs may be different in yeast.

Classification of GPCRs
GPCRs have been organized into groups or classes based on different criteria including
how their ligand binds, as well as physiological and structural features of the receptors. The most
commonly used systems classify the GPCRs into 6 clans A, B, C, D, E, and F to include all
GPCRs in animals and fungi based on sequence similarity in their transmembrane domains
(25,26). Each clan is again divided into families based on common biochemical properties
(Table 1.1). Human GPCRs have been recently classified into five families using a GRAFS
(Glutamate, Rhodopsin, Adhesion, Frizzled/taste2, Secretin) system that is based on
phylogenetic relationship in the transmembrane regions: rhodopsin (clan A), secretin (clan B),
glutamate (clan C), adhesion, and frizzled/taste2 receptor families (4). Additionally, some
GPCRs in humans could not be classified into any of the families, as sequences were very
divergent. However, the other receptors clearly form five families as determined by the extensive
phylogenetic analyses. Members of four of the five families all have long N termini. The
exception is the members of the rhodopsin family; most members of the rhodopsin family have
short N-termini, however there are instances of members with long N-terminal domains.
The rhodopsin family (class A) has the largest number of receptors. Currently, there are
more than 700 receptors in this family as recognized by the IUPHAR database (International
Union of basic and clinical PHARmacology, http://www.iuphar-db.org/) (27). The members of
4

the rhodopsin family share several characteristics. Most members of the rhodopsin family
contain the NSxxNPxxY motif in transmembrane domain VII (TMVII), and the D(E)-R-Y(F) or
“DRY” motif or at the border between transmembrane domain III (TMIII) and intracellular loop
2 (IL2). The ligands for most of the rhodopsin receptors bind within a cavity between the TM
regions (28).

The receptors of the secretin family (class B – 55 receptors as recognized by the
IUPHAR database (27)) bind large peptide ligands that share high sequence similarity and most
often act in a paracrine manner. The N-termini of these receptors are long (∼60 and 80 amino
acids), and contain conserved Cys-Cys bridges that are important for ligand binding. This family
consists of peptide and neuropeptide hormone receptors, such the secretin, calcitonin (CALC),
vasoactive intestinal peptide (VIP), glucagon (GCG), parathyroid hormone (PTH), and pituitary
adenylyl cyclase-activating protein (PACAP) receptors.

5

Table 1.1. Sequence-based groupings within the G-protein-coupled receptors
Clan A: rhodopsin-like receptors
Family I

Olfactory receptors, adenosine receptors, melanocortin receptors, and others

Family II

Biogenic amine receptors

Family III

Vertebrate opsins and neuropeptide receptors

Family IV

Invertebrate opsins

Family V

Chemokine, chemotactic, somatostatin, opioids, and others

Family VI

Melatonin receptors and others

Clan B: calcitonin and related receptors
Family I

Calcitonin, calcitonin-like, and CRF receptors

Family II

PTH/PTHrP receptors

Family III

Glucagon, secretin receptors and others

Family IV

Latrotoxin receptors and others

Clan C: metabotropic glutamate and related receptors
Family I

Metabotropic glutamate receptors

Family II

Calcium receptors

Family III

GABA-B receptors

Family IV

Putative pheromone receptors

Clan D: STE2 pheromone receptors
Clan E: STE3 pheromone receptors
Clan F: cAMP receptors and archaebacterial opsins

Table adapted from Flower (29)
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The glutamate receptor family (class C) consists of eight metabotropic glutamate
receptors (GRM), two gamma-aminobutyric acid (GABA) receptors (GABAB1 GABAB2;
functional GABA receptors contain both GABAB1 and GABAB2 subunits), a single calciumsensing receptor (CASR), three receptors that are believed to be taste receptors (TAS1) and
seven orphan receptors (27). All receptors of this family contain long N-terminus. In particular,
the metabotropic glutamate receptors contain a very long N terminus (∼280 to 580 amino acids)
that forms two distinct lobes separated by a cavity in which glutamate binds, forming the socalled “Venus fly trap” where the glutamate causes the lobes to close around the ligand. The
CASR also has a long, cysteine-rich N terminus, which is important for mediating calcium
signaling, although it is not known if it is involved in Ca2+ binding. The GABA receptors have a
long N-terminus that contains the ligand-binding site but lacks the cysteine-rich domain found in
the other receptors of this family. The TAS1 receptors are expressed in the tongue and believed
to mediate taste signals. These receptors also have a long N terminus with a series of conserved
Cys residues.
The members of the adhesion family of GPCRs contain N-termini of variable length
(~200 to ~2800 amino acids) and are often rich in glycosylation sites and proline residues. The
long N-termini of these GPCRs contain motifs that are likely to participate in cell adhesion
(30,31).

The frizzled/taste2 receptor family includes two groups: the frizzled and the TAS2
receptors. There are several consensus motifs (IFL in TMII, SFLL in TMV, and SxKTL in
TMVII) in the members of this family which are not found in the other four families. The TAS2
receptors are expressed in the tongue and palate epithelium, and are believed to function as bitter
taste receptors (4). These receptors have a very short N terminus that is unlikely to contain a
7

ligand-binding domain. Members of the frizzled family of receptors have a long N-terminus
(~200-amino acid) with conserved cysteines that are believed to be involved in ligand binding.
The receptors of this family are responsible for controlling cell fate, proliferation, and polarity
during metazoan development (4,32,33). Like other eukaryotic organisms, fungi also possess
GPCRs that are responsible for sensing extracellular signals. Fungal GPCRs are described later
in a separate section.
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GPCR Crystal Structures
Structural information for GPCRs is vital to understand how these signaling molecules
carry out their function. This information is also essential for drug design and development.
Although structures of a number of GPCRs have been obtained, information about the structurefunction relationships of GPCRs is still in its infancy. (34-36). The methods available for use to
gain structural information of proteins include X-ray crystallography, electron microscopy or
diffraction, NMR spectroscopy and molecular modeling. All of these methods require high
concentrations of purified protein. Additionally, crystallization and NMR require proteins in
media that provide a good environment for study. In order to maintain their native structures,
membrane proteins are required to be maintained in a lipid-like environment making the
structural studies by crystallization and NMR more challenging. In fact, crystallization of GPCRs
was one of the most challenging subjects in structural biology due to the poor natural abundance
and high intrinsic flexibility of these membrane proteins. Bovine rhodopsin was the first GPCR
to be crystallized about a decade ago by Palczewski et al (37). However, it took several years to
solve the crystal structure of a second GPCR (beta 2 adrenergic receptor) in 2007 (38,39). Since
then there has been almost an exponential growth in the number of solved structures due to the
application of several innovative protein engineering techniques and crystallography methods.
Currently there are 75 crystal structures of 18 GPCRs that have been solved (see Table 1.2)
adapted from Maeda 2013) (40). These structures provide insights into the structural and
functional diversity of these receptors and will be helpful to discover the molecular signatures of
the GPCRs. These structures will also aid in understanding the molecular changes that occur
during receptor activation. The structural data combined with data from the biophysical,
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biochemical and computational studies will allow us to understand the structure-function
relationships of GPCRs.
Due to the tremendous diversity of GPCRs and their involvement in so many pathways in
the cell, there remains a huge potential for the development of drugs to ameliorate many diseases
including neurological disorders, inflammatory diseases, cancer and metabolic imbalances.
Therefore, structures of more GPCRs and understanding the molecular mechanism of receptor
activation is important for fundamental biology as well as for improving human health by
facilitating structure-based in-silico drug discovery and the development of drugs with improved
specificity and pharmacodynamics.
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Table 1.2. GPCR structures solved in the 2000-2013 period
GPCR

Species Year PDB code Reference

Rhodopsin

Bovine

2000

1F88

(37)

1 Adrenergic

Turkey

2008

2VT4

(41)

2 Adrenergic

Human

2007

2R4R

(38)

D3 dopamine

Human

2010

3PBL

(42)

H1 histamine

Human

2011

3RZE

(43)

M2 muscarinic acetylcholine Human

2012

3UON

(44)

M3 muscarinic acetylcholine Rat

2012

4DAJ

(45)

A2A_Adenosine

Human

2008

3EML

(46)

Chemokine CXCR4

Human

2010

3ODU

(47)

Chemokine CXCR1

Human

2012

2LNL

(48)

-Opioid

Mouse

2012

4DKL

(49)

-Opioid

Human

2012

4DJH

(50).

-Opioid

Mouse

2012

4EJ4

(51)

N/OFQ opioid

Human

2012

4EA3

(52)
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Table 1.2 continued
GPCR

Species

Year

PDB code

Reference

Neurotensin

Rat

2012

4GRV

(53)

PAR1

Human

2012

3VW7

(54)

Sphingosine

Human

2012

3V2W

(55)

Smoothened

Human

2013

4JKV

(56)

Serotonin 5-

Human

2013

4IAR

(57)

receptor

1-phosphate

HT1B

Table adapted from Maeda (40).

Fungal GPCRs
Like many other eukaryotic organisms, fungi also possess GPCRs that respond to
extracellular signals to ensure proper cellular response. Although many GPCRs have been
identified in different fungi, only a few were included in the GPCR classification system (A-F
system, Table 1.1) described in the previous section (29). As a result, the fungal GPCRs have
been categorized separately into six classes based on sequence homology and ligand sensing
(Table 1.3). These are Ste2p-like pheromone receptors, Ste3p-like pheromone receptors,
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carbon/amino acid receptor, putative nutrient receptor, cAMP receptor-like, and microbial opsin
(22).
Although a number of GPCRs have been identified in fungi based on conserved
sequences and structures, only a few are well studied. Specifically the Saccharomyces cerevisiae
mating pheromone receptors Ste2p and Ste3p have been studied more extensively than the other
GPCRs due to the availability of whole genome sequence and the ability to manipulate easily. In
fact, the studies on S. cerevisiae GPCR system have considerably advanced our understanding
the mating system at molecular level.
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Table 1.3. Six classes of GPCRs in fungi

Species

Ste2-like
pheromo
ne
receptor

Ste3-like
pheromo
ne
receptor

Carbo
n/amin
o acid
recepto
r

Putative
nutrient
receptor

cAMP
receptorlike

Microbial
Opsin

–

–

Saccharomyces
cerevisiae

Ste2

Ste3

Gpr1

SCRG_01312
SCRG_02823
SCRG_00179

Schizosaccharo
myces pombe

Mam2

Map3

Git3

Stm1

–

–

Candida
albicans

Ste2

Ste3

Gpr1

CAWG_02899
CAWG_06059
CAWG_02686

–

–

GprB

GprC
GprD
GprE

GprF GprG
AN5720

GprH
GprI
AN8262
Afu3g017
50
Afu5g041
40
Afu3g007
80
Gpr-1
Gpr-2
Gpr-3
MGG_06
738

Aspergillus
nidulans

GprA

Aspergillus
fumigatus

Afu3g143 Afu5g078
30
80

Afu7g0
4800

Afu5g04100
Afu1g06840
Afu1g11900

Neurospora
crassa

Pre-2

Pre-1

Gpr-4

Gpr-5 Gpr-6

Magnaporthe
grisea

MGG_04
711

MGG_06
452

MGG_
08803

MGG_04698
MGG_02855

Cryptococcus
neoformans

–

Ste3α/Ste
3a Cpr2

Gpr4

Gpr2 Gpr3

Gpr4
Gpr5

Ustilago maydis

–

Pra1 Pra2

–

UM06006
UM01546

UM03423

–

Rcb1
Rcb2
Rcb3
CC1G_02
129

CC1G_07132
CC1G_04180

CC1G_02
288
CC1G_02
310

Coprinopsis
cinerea

–

AN3361

Afu7g014
30

Nop-1
ORP-1
MGG_090
15
CNAG_03
572
(Ops1)
UM02629
UM04125
–

Table adapted from Xue et. al. (22)
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S. cerevisiae GPCRs
GPCR studies using mammalian systems can be extremely complex due to cross-talk
between different types of receptors and the assortment of G proteins present that can regulate
multiple pathways. In constrast, the unicellular, genetically tractable eukaryotic organism S.
cerevisiae provides a simple biological system with only a few GPCRs and G proteins (58,59). S.
cerevisiae has only three GPCRs: Ste2p, Ste3p and Gpr1p. Ste2p and Ste3p are mating
pheromone receptors and Gpr1p is a carbohydrate sensor. Although the pheromone and the
carbohydrate sensing receptors share some downstream components, no cross-talk occurs
between these two receptor systems as they couple to two different G proteins. The mitogenactivated protein kinase (MAPK) pathway activated by the GPCRs of this organism exhibits high
homology to that of the mammalian system (60). In spite of little sequence similarity to the
endogenous yeast GPCRs, several mammalian GPCRs were successfully expressed in yeast and
were capable of activating the MAPK pathway (59,61,62). Yeast GPCRs have also been shown
to exhibit signaling when expressed in mammalian cells (63).
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S. cerevisiae exists as a haploid or diploid cell (64). The haploid cells exist as one of two
mating types, MATa and MATα, which are distinguished by the expression of a set of genes
involved in mating that are not expressed by the diploids. MATa cells express the GPCR Ste2p
and the pheromone a-factor, a hydrophobic, farnesylated, carboxymethylated, dodecapeptide
with the sequence YIIKGVFWDPAC(Farnesyl)-OCH3. MATα cells express the GPCR Ste3p
and the pheromone α-factor, a tridecapeptide with the sequence WHWLQLKPGQPMY. The
pheromones a- and α-factor, bind to Ste3p and Ste2p, respectively, initiating the mating and
eventual fusion of the two haploid cells resulting in a diploid cell (Figure 1.2). Pheromone
binding causes a conformational change in the receptor that triggers the activation of the
intracellular heterotrimeric G proteins consisting of Gpa1p (Gα), Ste4p (Gβ) and Ste18p (Gγ)
leading to the G1 cell cycle arrest, polarized growth, dissolution of the cell wall and membranes
followed by cellular fusion (65). Receptor activation triggers the exchange of GDP with GTP at
Gpa1p (Gα) subunit releasing the Ste4p/Ste18p (Gβγ) dimer which in turn transmits the signal
required for mating. The Gpa1p (Gα) may also promote signaling via the RNA binding protein
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Scp160, although the mechanism is unknown (66).

Figure 1.2. Pheromone mediated mating in Saccharomyces cerevisiae. Schematic
representation of the pheromone/receptor mediated communication between MATa and
MATα haploid cells prior to mating. The α-factor pheromone expressed by the MATα cells
binds with Ste2p expressed on the cell surface of MATa cells. The a-factor pheromone
expressed by the MATa cells binds with Ste3p expressed on the cell surface of MATα cells.
Pheromone binding activates the receptors resulting in initiation of signaling involving the
MAP kinase cascades, and activation of mating specific genes ultimately resulting in the
fusion of the two haploid cells.
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The Ste4p/Ste18p complex transmits the signal to a mitogen-activated protein (MAP)
kinase cascade through at least three effector proteins: (i) Ste20, a p21-activated protein kinase,
(ii) Ste5, a scaffold protein that coordinates the MAPK pathway, and (iii) Far1, a protein
involved in cell cycle control (65,67-69). Ste20 phosphorylates and activates Ste11 (MAPKKK),
the first kinase in the MAPK pathway, which in turn drives a series of phosphorylation reactions
involving Ste7 (MAPKK) and Fus3 (MAPK) (70,71). Phosphorylated Fus3 activates Ste12, the
transcription factor required for the expression of mating genes. Fus3 also phosphorylates and
inactivates Dig1 and Dig2, two negative regulators of the transcription factor Ste12 (65,72). The
scaffold protein Ste5p serves to facilitate interactions among Ste11, Ste7 and Fus3 and delivers
these proteins to the plasma membrane via its associated G protein  subunit (73-75). In
addition, Ste5 has been shown to also limit cross-talk between alternative MAPK signaling
pathways. Ste5 increases the affinity of Ste7 for Fus3 over Kss1 during response to pheromone.
Ste7 preferentially targets the Kss1 kinase during filamentous growth (e.g., upon nitrogen
starvation) (76). Fus3 phosphorylates and activates Far1 (72), which inhibits Cdc28-G1 cyclin
complex thereby promoting cell cycle arrest (77). The transcriptional transactivator Ste12p binds
to the pheromone response element (PRE) at the promoter region of target genes such as FUS1,
FUS2, FIG1, FIG2, and AGA1 that are induced for cell fusion (78). The two haploid cells of the
opposite mating types form shmoos, (79) followed by degradation of the cell wall, plasma
membrane and finally fusion of their nuclei to become one a/α diploid zygote (80).
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Figure 1.3. Schematic diagram of the mating MAPK signaling cascade in S. cerevisiae.
Activation of the pheromone receptor after binding with pheromone (α-factor) leads to the
exchange of GDP with GTP in the G protein α subunit (Gpa1). This results in dissociation
of Gα from the G protein βγ subunits (Ste4 and Ste18). Free βγ activates a downstream
signaling cascade through the guanine nucleotide exchange factor Cdc24, the protein
kinase Ste20, and the kinase scaffold protein Ste5. The MAP kinase Fus3 phosphorylates
and activates the transcription factor Ste12, resulting in new gene transcription
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Like many other eukaryotic GPCRs, the mating pathway in yeast is highly regulated by
several mechanisms. The extracellular protease Bar1p produced by the MATa cell cleaves αfactor (81) allowing the cells to recover from α-factor induced growth arrest. Sst2p, a member of
the regulator of G-protein signaling (RGS) protein family, interferes with GTP-bound Gpa1p and
down-regulates mating signal (82). Yeast casein kinases, Yck1p and Yck2p, are involved in
budding morphogenesis and internalization of pheromone receptors (83). Yck-mediated
phosphorylation of the mating receptors is required for vesicle trafficking at the cell membrane
(84). Eventually phosphorylation at the C-terminus of the receptor leads to ubiquitination,
internalization and degradation (85).
Taking advantage of the simplicity of the yeast system and the power of yeast genetics
along with the low cost of yeast cell culture, the yeast GPCR system have enabled many
researchers worldwide to use it as a model for structure-function analysis of GPCRs. Moreover,
yeast GPCRs in a haploid cell can replaced with a mammalian GPCR and the mating pathway
can be activated. Heterologous expression of mammalian GPCRs in a yeast host has enabled
researchers to develop cell-based functional assays in a eukaryotic system free from cross-talk
with other GPCRs and can be used for ligand identification and pharmacological characterization
(59,61,63).

The use of Ste2p as a model GPCR
Ste2p, the α-factor pheromone receptor of S. cerevisiae, shares common architectural
organization of GPCRs with the signature seven transmembrane domains. Although there is no
significant sequence homology across the members of the GPCR superfamily, their mechanism
of signal transduction is thought to be similar. In fact, comparative analysis of two widely
divergent GPCRs, Ste2p (a Class D GPCR) and rhodopsin (a Class A GPCR) exhibited several
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similarities (20). For example, ligand binding occurs within the core of the 7TM helices (86-88);
the third intracellular loop plays key roles in G protein activation (89-91);.and the C-terminus is
the target for desensitization by phosphorylation and ligand-mediated down-regulation by
receptor endocytosis (92,93). In addition, conserved residues important for receptor function are
located in TM1 and TM3 of both receptors. Strongly polar amino acids in Ste2p that mediate
helix interactions are also located in similar positions in rhodopsin. Mutation of these residues
leads to phenotypic changes such as loss of function or constitutive activity. In both receptors,
small and weakly polar amino acids located in identical positions (TM domains) facilitate tight
helix packing. Location of conserved amino acids and sites of constitutively active mutations are
located in TM3, TM6 and TM7. Proline is essential at similar positions in TM6 and TM7. Thus
these structure-function similarities provide strong support that the underlying mechanism of
signal transduction in these receptors is similar.
Although there has been an explosion of X-ray crystal structures of GPCRs since 2007,
X-ray crystallography of Ste2p is still not possible due to difficulties in obtaining sufficient
amount of pure protein. As a result, structure-function information of Ste2p has been mainly
obtained by mutational analysis. Substituted Cysteine Accessibility method (SCAM), modeling,
and biophysical analysis have been used in several studies to obtain structural information for
Ste2p. A recent study using SCAM proposed that the N-terminus has a β-strand between residues
20-30 and that this β-strand participates in homodimer formation (94). Another study using
SCAM by Hauser et al. proposed that residues 106-114 in the EL1 form a 310 helix (95). More
details describing the N-terminus and its role in dimerization of Ste2p will be discussed in
chapter 2 of this dissertation. Modeling and biophysical studies by Akal-Strader et. al. predicted
that the C-terminus of the EL1 comprising residues 126-135 contain two short β-strands (96).
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The solvent accessibility of the several residues were also reported to change in a liganddependent manner. Hauser et. al. proposed that part of the EL1 is buried in a solvent-inaccessible
environment and that this part interacts with the extracellular part of the transmembrane domains
5 and 6. Choi and Konopka (97) used SCAM to determine the TM boundaries. They proposed
that TM domains of Ste2p vary in length and that some TM domains are tilted relative to the
plane of the membrane in a manner similar to that described in the crystal structure of rhodopsin.
Ste2p is activated upon binding to the α-factor pheromone (WHWLQLKPGQPMY), a 13residue peptide. Analysis of α-factor using alanine scanning mutagenesis studies indicated that

residues near the N-terminus (Trp1-Leu4) of this peptide are involved in receptor activation and
signal transduction, while residues near the C-terminus (Gln10-Tyr13) are associated with ligand
binding (58,98). The central region consisting of residues Lys7-Gln10 assumes a -turn structure
that has been shown to be critical for proper orientation of the signaling and the binding domains
of the peptide (99-101). It was also demonstrated that deletion of the last two residues
(Met12Tyr13) from the peptide results in a peptide that does not show any significant binding and
does not block the binding of the full-length 13-residue peptide, but instead enhances the activity
the intact peptide. It was demonstrated that this 11-residue peptide (WHWLQLKPGQP) enhances
the signaling activity of Ste2p when it is added to the wild type thereby acting as a synergist (102). It
was also shown that deletion of the N-terminus results in a peptide that lowers the signaling activity
of the full-length pheromone thereby acting as an antagonist (103). Thus studies with -factor
suggested that three regions of the peptide plays three different roles, each being dedicated to a
certain function.
Cross-linking studies using unnatural amino acid p-benzoylphenylalanine (Bpa) at various
positions of -factor indicated that residues Trp1, Trp3, Gln5 and Tyr13 residues of -factor interact
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with residues at the extracellular ends of TM5-TM7 and portions of EL2 and EL3 close to these TMs
(104). Several studies indicated that Tyr13 of -factor may interact directly with a region of Ste2p
(Phe55-Arg58) at the extracellular end of TM1 (86,104,105). In studies using alanine scanning
mutagenesis, Lee et al. showed that Tyr266 in the extracellular end of TM6 may be part of the
ligand-binding pocket. Tyr266 recognizes the N-terminal portion of -factor, and upon ligand
binding is involved in the transformation of Ste2p into an activated state (106). Later, Tyr266 was
shown to interact with Asn205 (107,108). The 10th residue (Gln10) of -factor was shown to be
adjacent to Ser47 and Thr48 of Ste2p (109). Studies by Bajaj et. al. using a fluorescent alpha-factor
analogue fluorescent α-factor analogue [K7(NBD),Nle12]α-factor in conjunction with flow
cytometry and fluorescence microscopy suggested that the -factor binds to the receptor in a twostep process: an initial interaction in which the ligand is placed in a hydrophobic environment
followed by a conversion to a state in which the ligand moves to a more polar environment (110).
Based on these studies a model of ligand binding to the receptor was suggested by our lab (58).
According to this model, the α-factor bends around the Gly9-Gln10-Pro11 residues and carboxyl
terminal residues Gln10-Pro11-Met12-Tyr13 side chains of α-factor interact with TM1 of the receptor.
while the N-terminal residues Trp1 and Trp3 side chains interact with a pocket formed by TM6ECL3-TM7. (58).

Interactions among proteins play essential roles in the organization and function of
cellular signaling. GPCRs have been considered to exist and function as monomers for many
years. However, an increasing number of studies demonstrated that GPCRs are able to form
dimers or higher order oligomers. Several studies reported that dimerization and /or
oligomerization are often essential for modulation of receptor function (Table 1.4) (10,111-117).
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Table 1.4. Proposed roles of GPCR dimerisation/oligomerisation
Role of dimerisation/

Receptor(s)

References

β2-adrenoceptor

(118)

CXCR1

(119)

α2-adrenoceptors

(120)

TSH receptor

(121)

Frizzled 4

(122)

Calcium sensing receptor

(123)

Melacortin-1 receptor

(124)

oligomerisation
Protein folding

CXCR1–CXCR2 hetero-dimer (119)
Efficient signal transduction

Rhodopsin

(125,126)

BLT1 leukotriene B4 receptor

(127)

G-protein selectivity (hetero- MOP and DOP receptors

(128,129)

dimers)

(130,131)

D1 and D2 dopamine
receptors

Signal

alteration/modulation Orexin-1 receptor and

(hetero-dimers)

(132)

cannabinoid CB1
Melatonin MT1 and GPR50

(133)

MrgD and MrgE

(134)

DOP receptor and SNSR-4

(135)

Somatostatin sst2a and sst3

(136)
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Table 1.4 continued
Role of dimerisation/

Receptor(s)

References

oligomerisation
Control

of

physiological DOP and KOP receptors

function (heterodimers)

Angiotensin

(137)

AT1 and (138,139)

Bradykinin B2
Angiotensin AT1 and Mas

(140,141)

EP1 prostanoid receptor and (142)
β2-adrenoceptor
Various

adenosine

and (143-146)

dopamine receptors
Adenosine A1 and A2A
Dopamine

D2

(147)
and (148)

cannabinoid CB1?

Table adapted from Milligan 2007 (111).
Ste2p has also been identified in oliogmers in intact cells and membranes, although the
functional significance of this oligomerization/dimerization is not clear. Gehret et. al. (149) used
bioluminescence resonance energy transfer (BRET) to demonstrate that co-expressed Ste2p
tagged with Renilla luciferase or a modified green fluorescent proteins co-oligomerize. Their
study indicated that individual receptors that form oligomers do not act independently. In an
analysis of Ste2p mutants using fluorescence resonance energy transfer (FRET) Overton and
Blumer (150) demonstrated that the N-terminus, TM1 and TM2 mediate oligomerization of
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Ste2p. Another study used disulfide cross-linking to demonstrate that TM1 and TM4 are dimer
interfaces of Ste2p (151). These two transmembrane domains have also been reported to be
dimer contacts in rhodopsin, a class A GPCR, providing evidence that structure and function are
highly conserved across GPCRs (151). A study by Kim et. al. demonstrated that TM1 and TM7
of Ste2p also participate in dimerization. They demonstrated that the dimers formed by TM7
changes upon receptor activation (152). More recently, Umanah et al. demonstrated that IL3 of
Ste2p also participates in the dimerization (153). Uddin et al. (94) demonstrated that the Nterminus of Ste2p also participates in Ste2p dimerization. Thus, several domains of Ste2p have
been found to be associated with oligomerization/dimerization, although the precise, functional
significance of this observation still unclear. In chapters 2, 3 and 4 of this dissertation,
dimerization of Ste2p is discussed in more detail.
This dissertation describes the role of extracellular N-terminus of Ste2p and its
interaction with extracellular loop 1. In Chapter 2, substituted Cysteine Accessibility Method
(SCAM) was used to determine the solvent accessibility of the N-terminus. This chapter also
discusses the possible structure of the N-terminus and its role in receptor dimerization. Chapter 3
describes the role of the N-terminus in receptor function. The interaction between the N-terminus
and the extracellular loop 1 is discussed in Chapter 4. Finally, Chapter 5 is an overall evaluation
of these studies and future directions. This experimental results presented in this dissertation will
provide a better understanding of the structure of the N-terminus of Ste2p and how this structure
plays a role in regulation of receptor function. Ultimately these studies will be aid in the
understanding of structure-function relationships which regulate receptor signaling.
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My contribution to this paper was to make Ste2p mutants, determination of signaling activities
and accessibility of the residues, and much of the literature review and writing.
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Abstract
G protein-coupled receptors (GPCRs) are members of a superfamily of cell surface
signaling proteins that play critical roles in many physiological functions; malfunction of these
proteins is associated with multiple diseases. Understanding the structure-function relationships
of these proteins is important, therefore, for GPCR-based drug discovery. The yeast
Saccharomyces cerevisiae tridecapeptide pheromone α-factor receptor Ste2p has been studied as
a model to explore the structure-function relationships of this important class of cell surface
receptors. Although transmembrane domains of GPCRs have been examined extensively, the
extracellular N-terminus and loop regions have received less attention. We have used the
substituted cysteine accessibility method (SCAM) to probe the solvent accessibility of single
cysteine residues engineered to replace residues Gly20 through Gly33 of the N-terminus of
Ste2p. Unexpectedly, our analyses revealed that the residues Ser22, Ile24, Tyr26, and Ser28 in
the N-terminus were solvent inaccessible, whereas all other residues of the targeted region were
solvent accessible. The periodicity of accessibility from residues Ser22 to Ser28 is indicative of
an underlying structure consistent with a -strand that was predicted computationally in this
region. Moreover, a number of these Cys-substituted Ste2p receptors (G20C, S22C, I24C, Y26C,
S28C and Y30C) were found to form increased dimers compared to the Cys-less Ste2p. Based on
these data, we propose that part of the N-terminus of Ste2p is structured and that this structure
forms a dimer interface for Ste2p molecules. Dimerization mediated by the N-terminus was
affected by ligand binding indicating an unanticipated conformational change in the N-terminus
upon receptor activation.
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Introduction
G protein-coupled receptors (GPCRs) belong to a superfamily of cell surface signaling
proteins that play pivotal roles in many physiological processes including responses to hormones
and neurotransmitters as well as being responsible for vision, olfaction and taste (1). Malfunction
of GPCRs is associated with multiple diseases including Alzheimer’s, Parkinson’s, diabetes,
color blindness, asthma, depression, hypertension, stress, cardiovascular, and immune disorders.
Because these receptors are involved in a wide range of cellular functions, modulation of GPCR
function is an important therapeutic goal with about 40-50% of drugs used in clinical medicine
designed to affect GPCRs (2-4). Nonetheless, only a fraction of the GPCR superfamily is
targeted by current drugs (5).
To date detailed atomic-level structural information for seven GPCRs has been obtained
(6-12). These crystal structures have played a crucial role in understanding the structure-function
relationships of these receptors. However, further structural information for additional GPCRs is
vital for a more comprehensive understanding of receptor function and ultimately for drug
development (1, 2, 13). In addition, most of the studies have revealed structural information
focused on the transmembrane domains, although a large portion of all GPCRs is composed of
intracellular and extracellular loops as well as N- and C- termini. These regions have received
less consideration with respect to structural analysis because many of the crystals analyzed
contained a large unnatural replacement within the third intracellular loop and the extracellular
regions were not always visualized. It is generally believed that the loop regions and N- and Ctermini are flexible and all the residues in the extracellular domains are solvent accessible.
However, accessibility analysis of extracellular loop 1 of Ste2p indicated that all extracellular
residues are not accessible; and the accessibility of some residues changes upon receptor
activation (14). Therefore, we decided that a rational first approach to studying the structure and
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function of the N-terminus was to probe systematically its solvent accessibility by the substituted
cysteine accessibility method (SCAM) so that we might uncover structural elements of the Nterminus and their functional roles. Solvent accessibility determines whether particular Cys
residues are in a hydrophilic or hydrophobic environment. Residues that face the low dielectric
of the membrane or are located in tightly packed regions are inaccessible to a highly soluble,
hydrophilic SCAM reagent. Conversely, Cys residues that react well with the reagent are
predominantly exposed to a hydrophilic milieu outside the membrane or are not packed closely
in a solvent excluding environment.
We carried out Cys scanning mutagenesis of residues G20 to G33 of Ste2p and probed
the solvent accessibility of the Cys residue in these mutant receptors using SCAM (15, 16). Our
analysis revealed a periodicity of accessible residues in the N-terminus which supported the
computational prediction of a β-strand in this portion of Ste2p. In addition, we observed that
certain Cys residues in the N-terminus promoted dimer formation suggesting the involvement of
a 14-amino acid region of the N-terminus in Ste2p dimerization.
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Methods
Media, Reagents, Strains, and Plasmids: S. cerevisiae strain LM102 [MATa ste2 FUS1lacZ::URA3 bar1 ura3 leu2 his4 trp1 met1] (17) was used for growth arrest, FUS1-lacZ gene
induction and saturation binding assays, and the protease-deficient strain BJS21 [MATa, prc1407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (18) was used for protein isolation, SCAM
and immunoblot analyses to decrease receptor degradation during analyses (19). The plasmid
pBEC2 containing C-terminal FLAG™ and His-tagged STE2 (14) was transformed by the
method of Geitz (20). Transformants were selected by growth on yeast media (21) lacking
tryptophan (designated as MLT) to maintain selection for the plasmid. The cells were cultured in
MLT and grown to mid log phase at 30°C with shaking (200 rpm) for all assays.

Growth Arrest Assays: S. cerevisiae LM102 cells expressing Cys-less Ste2p and single Cys
mutants were grown at 30°C overnight in MLT, harvested, washed three times with water, and
resuspended at a final concentration of 5×106cells/mL (22). Cells (1 mL) were combined with
3.5 mL of agar noble (1.1%) and poured as a top agar lawn onto a MLT medium agar plate.
Filter disks (BD, Franklin Lakes, NJ) impregnated with α-factor (2, 1, 0.5, 0.25 and 0.125
µg/disk) were placed on the top agar. The plates were incubated at 30°C for 24h and then
observed for clear halos around the disks. The experiment was repeated at least three times, and
reported values represent the mean of these tests.

FUS1-lacZ Gene Induction Assay: LM102 cells expressing Cys-less Ste2p and single Cys
mutants were grown at 30 ºC in selective media, harvested, washed three times with fresh media
and resuspended at a final concentration of 5 x 107 cells/mL. Cells (500 µl) were combined with
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α-factor pheromone (final concentration of 1μM) and incubated at 30ºC for 90 min. The cells
were transferred to a 96-well flat bottom plate (Corning Incorporated, Corning, NY) in triplicate,
permeabilized with 0.5% Triton X-100 in 25 mM PIPES buffer (pH 7.2) and then βgalactosidase assays were carried out using fluorescein di-β-galactopyranoside (Molecular
Probes, Inc., Eugene, OR) as a substrate as described previously (18, 23). The reaction mixtures
were incubated at 37°C for 60 min and 1.0 M Na2CO3 was added to stop the reaction. The
fluorescence of the samples (excitation of 485 nm and emission of 530 nm) was determined
using a 96-well plate reader Synergy2 (BioTek Instruments, Inc., Winooski, VT). The data were
analyzed using Prism software (GraphPad Prism version 5.03 for Windows, GraphPad Software,
San Diego CA). The experiments were repeated at least three times and reported values represent
the mean of these tests.
Binding Assays: Tritiated [3H] α-factor (9.33 Ci/mmol) prepared as previously described (24)
was used in saturation binding assays on whole cells. LM102 cells expressing Cys-less or single
Cys mutant of Ste2p were harvested, washed 3 times with YM1 (25), and adjusted to a final
concentration of 3 × 107cells/mL. Cells (600 µL) were combined with 150 µL of ice-cold 5X
binding medium (YM1 plus protease inhibitors [YM1i ](25) supplemented with [3H]α-factor and
incubated at room temperature for 30 min. The final concentration of [3H]α-factor ranged from
0.5 × 10−10 to 1 × 10−6 M. Upon completion of the incubation interval, 200 µL aliquots of the
cell-pheromone mixture were collected in triplicate and washed over glass fiber filter mats using
the Standard Cell Harvester (Skatron Instruments, Sterling, VA). Retained radioactivity on the
filter was counted by liquid scintillation spectroscopy. LM102 cells lacking Ste2p were used as a
nonspecific binding control for the assays. Binding assays were repeated a minimum of three
times, and similar results were observed for each replicate. Specific binding for each mutant
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receptor was calculated by subtracting the nonspecific values from those obtained for total
binding. Specific binding data were analyzed by nonlinear regression analysis for single-site
binding using Prism software (GraphPad Software, San Diego, CA) to determine the Kd and Bmax
values for each mutant receptor.

Immunoblots: BJS21 cells expressing Cys-less or single Cys mutants grown in MLT were used
to prepare total cell membranes isolated as previously described (25). Protein concentration was
determined by BioRad protein assay (BioRad, Hercules, CA)(14), and membranes were
solubilized in sodium dodecyl sulfate (SDS) sample buffer (10% glycerol, 5% 2mercaptoethanol, 1% SDS, 0.03% bromophenol blue, 62.5 mM Tris, pH 6.8). For studies of
disulfide cross-linking, membranes were solubilized in SDS sample buffer without 2mercaptoethanol. Proteins were fractioned by SDS−PAGE (10% acrylamide) along with prestained Precision Plus protein standards (BioRad) and transferred to an ImmobilonTMP
membrane (Millipore Corp., Bedford, MA). The blot was probed with anti-FLAG™ M2
antibody (Sigma/Aldrich Chemical, St. Louis, MO), and bands were visualized with the West
Pico chemiluminescent detection system (Pierce). The total intensity of all Ste2p bands in
each lane was determined using a ChemiDoc XRS photodocumentation system with
Quantity One one-dimensional analysis software (version 4.6.9, BioRad, Hercules, CA).
Multiple repeats of immunoblot experiments yielded similar results. Constitutively-expressed
membrane protein Pma1p was used as a loading control as described previously (26) using
Pma1p antibody (Thermo Scientific, Rockford, IL).
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Whole-cell MTSEA Labeling, Membrane Preparation, and Immunoblots:
MTSEA-biotin (2-((biotinoyl)amino)ethyl methanethiosulfonate) (Biotium, Hayward, CA)
labeling was performed as described previously (14). To eliminate reaction with native Cys in
Ste2p, all the mutants were constructed in a Cys-less receptor background. This Cys-less
receptor contained a FLAG™ epitope tag and a 6XHis tag at the C-terminus of the receptor.
Experiments were completed at least three times as described below. BJS21 cells expressing
single Cys mutations in Ste2p or Cys-less receptor were grown in MLT at 30°C overnight. Cells
were harvested at mid-log phase (A600 ~ 1.5), washed, and resuspended in phosphatebuffered saline (PBS; 10 mM Na2HPO4, 1.5 mM KH2PO4, 3.0 mM KCl, 150 mM NaCl, pH
7.4) at 20-fold concentration. One ml of this cell suspension was warmed to room temperature
and then supplemented with MTSEA-biotin (20 mM in dimethyl sulfoxide) to a final
concentration of 0.1 mM. The reaction was stopped after 2 min by the addition of ice-cold
citrate buffer to a final concentration of 50 mM (0.25M Citric Acid/KH2PO4, pH 4.0) and was
incubated on ice for an additional 5 min. The low pH has previously been shown to prevent
disulfide exchange reactions that might complicate the analysis (27). All subsequent steps were
performed at 4°C unless otherwise indicated. MTSEA-biotin-treated cells were pelleted,
resuspended in PBS, and lysed by vortexing with glass beads. Following a low speed spin (700
X g, 5 min) to remove cell wall debris, unbroken cells, and glass beads, the resulting
supernatant was centrifuged at high speed (15,000 X g, 30 min) to pellet membranes. The
pellet was resuspended in PBS, and protein concentration was determined using the
BioRad (BioRad, Hercules, CA) protein assay. Membranes were solubilized in RIPA buffer
(0.1% SDS, 1% Triton X-100, 0.5% deoxycholic acid, 1 mM EDTA in 1X PBS, pH 7.4)
for 1 h at room temperature with end-over-end mixing. The solubilized, biotinylated proteins
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were collected on UltraLink Immobilized Streptavidin Plus beads (Thermo
Scientific, Rockford, IL) by incubation overnight at 4°C with end-over-end mixing. The
beads were washed four times with ice-cold RIPA buffer, once with 2% SDS in PBS (room
temperature), followed by a final wash with ice-cold RIPA buffer. During the washes the
beads were resuspended and then allowed to settle by gravity for 20 min prior to removal of
the supernatant. Bound proteins were extracted from the beads using SDS sample buffer
(10% glycerol, 5% 2-mercaptoethanol, 1% SDS, 0.03% bromophenol blue, 62.5 mM Tris, pH
6.8, 55°C, 5 min) and used for immunoblot analysis. Solubilized proteins were resolved by
SDS-PAGE and immunoblotted using anti-FLAG™ M2 antibody as described under
“immunoblots” in Methods. To verify Ste2p expression levels, an aliquot of total membrane
proteins was solubilized in SDS sample buffer, fractionated by SDS-PAGE (5-10 µg/lane), and
immuno-blotted in parallel with the biotinylated proteins extracted from the beads.

Disulfide Cross-Linking with Cu-Phenanthroline: One hundred µg of membrane protein
preparation was treated with a fresh preparation (pH 7.4) of Cu(II)-1,10-phenanthroline (Cu-P;
final concentration, 2.5 μM CuSO4 and 7.5 μM phenanthroline). The reaction was carried out at
room temperature for 20 min, terminated with 50 mM EDTA, and kept on ice for 20 min
followed by adding SDS sample buffer without 2-mercaptoethanol. In experiments designed to
prevent disulfide bond formation, the membranes were treated with 5 mM NEM (Nethylmaleimide) for 20 min prior to incubation with Cu-P reagent. Alpha-factor or antagonist
(desW1,desH2-α-factor) (10 µM final concentration) were added to the membrane preparation
and incubation was allowed to proceed for 30 min prior to Cu-P treatment in experiments
performed to examine the influence of ligand on dimerization.

57

Results
Expression and Biological Activities of Single Cys and Cys-less Receptors
We targeted residues G20 to G33 in the N-terminus of Ste2p, which comprised the
predicted -strand (T23 to Y30) (28, 29) and an additional three residues on both the N- and Ctermini of the strand, for determining the solvent accessibility. To eliminate any non-specific
reactivity with MTSEA-biotin in SCAM experiments (reported below), we used the Cys-less
receptor that had been used previously for SCAM studies in our lab and those of others. In this
receptor, the two native cysteine residues at C59 and C252 were replaced with serine resulting in
a fully active receptor (30). Individual residues in the region of interest were replaced one at a
time with cysteine to generate a total of 14 Cys mutants of Ste2p. Before embarking on SCAM,
expression level and biological activities of each mutant receptor were measured.
For determination of total receptor expression levels, membranes from yeast cells harboring a
plasmid with each single Cys mutant receptor tagged with a FLAG- epitope were prepared, run
on SDS-PAGE under reducing conditions, and immunoblotted using the FLAG™ antibody. Two
additional single-Cys mutants (T199C and Y266C) were also studied as they served as controls
in SCAM experiments reported below. Multiple repeats of immunoblot experiments yielded
similar results and the standard deviation for each expression is indicated for each receptor
(Table 2.1). Representative blots are shown in figure 2.1. Relative total expression level of the
mutant receptors (monomers and dimers were both included in the calculated total expression;
dimer formation is examined in greater detail below) was compared to the Cys-less receptor and
normalized to the constitutively-expressed membrane protein Pma1p which was used as a
loading control (Table 2.1). Expression levels of different mutants varied from ~4 fold lower
(S22C) to ~1.6 fold higher (G31C) than the Cys-less Ste2p. Because SCAM experiments were
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carried out in whole cells using a membrane impermeable reagent, surface expression of the
receptors will directly affect the relative solvent accessibility of the mutants as reported below.
Therefore, surface expression of the mutants was measured by saturation binding assays using
tritiated [3H]α-factor in whole cells. Since the relative Bmax value from saturation binding
experiments represents the relative surface expression of a receptor, the Bmax values of the
mutants were compared to that of the Cys-less receptors. As shown in Table 2.1, mutant surface
expressions varied from ~5 fold lower (Y26C) to ~1.8 fold higher (T23C) as compared to the
Cys-less Ste2p. When experimental error was taken into account 9 of the 14 Cys mutants showed
a good correlation between the relative total expression and surface expression. Most
significantly, correlation was quite good for the poorly expressed (G20C, S22C and Y26C)
mutants. Three of the mutants (Q21C, T27C and N32C) showed a low surface expression
compared to total expression and two (T23C and Y30C) showed a higher relative surface
expression compared to total expression.
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Table 2.1. Relative expression levels of Ste2p
Relative Total
Expression

Relative Surface

Levela

Expression Levelb

Receptor
Cys-less

1.00

±

0.06

1.00 ± 0.01

T199C

0.81

±

0.10

1.25 ± 0.36

Y266C

0.72

±

0.13

1.14 ± 0.15

G20C

0.49

±

0.06

0.43 ± 0.13

Q21C

1.06

±

0.02

0.69 ± 0.05

S22C

0.25

±

0.06

0.20 ± 0.07

T23C

1.13

±

0.17

1.85 ± 0.05

I24C

0.64

±

0.20

0.75 ± 0.37

N25C

1.09

±

0.33

0.87 ± 0.36

Y26C

0.26

±

0.07

0.19 ± 0.04

T27C

1.35

±

0.21

0.78 ± 0.05

S28C

0.63

±

0.09

0.57 ± 0.21

I29C

1.33

±

0.08

1.57 ± 0.24

Y30C

0.95

±

0.14

1.51 ± 0.04

G31C

1.56

±

0.27

1.26 ± 0.07

N32C

1.30

±

0.13

0.76 ± 0.08

G33C

1.06

±

0.05

0.84 ± 0.05
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a

Relative expression level of the Cys mutants of Ste2p. Ste2p band intensity was quantitated by

Quantity One software (BioRad) and normalized to the Pma1p band intensity (amount of light
emitted from the chemiluminecent signal as read by Quantity One) (for protein loading on the
gel) and the Cys-less receptor. Expression level of each receptor on the same PAGE immunoblot
was calculated as

{

b

}

{

}

Relative surface expression Cys mutants of Ste2p. Surface expression was determined by

saturation binding assay using tritiated [3H] α-factor with whole cells. The surface expression of
receptors was determined from the Bmax values obtained from saturation binding assays using
tritiated [3H] α-factor with whole cells and the relative surface expression was expressed as
.
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Figure 2.1. Ste2p expression levels. Total membranes prepared from cells expressing single
Cys mutants of Ste2p (G20C to G33C, T199C, and Y266C) and the Cys-less receptor were
run on separate gels shown in the three panels. Five µg of total membrane preparations
from each mutant was immunoblotted using antibody against the C-terminal FLAG™
epitope tag. Molecular mass markers (kDa) are indicated on the left-hand side. M and D
indicate the monomeric and dimeric forms of Ste2p, respectively. The same blot was
stripped and then re-probed with anti-Pma1p antibody as a loading control.

The biological activities of each mutant were measured by growth arrest, reporter gene
activity, and binding assays and were normalized to those of the Cys-less receptor (Table 2.2).
Pheromone-induced growth arrest activity of all the mutants was similar to that of the Cys-less
receptor (between 85% and 103% of Cys-less receptor). One receptor, Y26C, was reported in a
previous study to fail to trigger growth arrest (29). We believe the discrepancy between our study
and that of Shi et al. (29) is due to differences in the strain background used. Signaling activity
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as measured by the pheromone-induced FUS1-lacZ reporter gene activation assay was between
57% (Y30C) and 127% (I24C) of the Cys-less receptor. Although expression of two receptors
[S22C (25%) and Y26C (26%)] was lower than 50%, these mutants exhibited effective growth
arrest and β-galactosidase activities suggesting that even the low expression of Ste2p was
sufficient to elicit a strong biological response to pheromone. Previous studies also indicated that
low levels of Ste2p were sufficient to manifest full biological responses (31-34). Finally, the
alpha-factor binding affinity of each mutant was measured by saturation binding assays using
whole cells. The binding affinity varied from ~50% (I29C) lower to ~50% (G33C) higher in
comparison to that of the Cys-less receptor (Table 2.2). From the results of the above
experiments, we conclude that all the single Cys mutants of Ste2p exhibited effective signaling
and strong binding, and therefore Cys substitution did not cause any global change in the
receptor conformation.
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Table 2.2. Biological activities of Cys-less and single Cys mutants of Ste2p

Receptor Growth Arrest Activity (%)a β-galactosidase Activity (%)b

Relative Kdc

100 ± 0.3

100 ± 2.0

1.00 ± 0.21

93± 7.0

96± 5.0

0.99 ± 0.20

89 ± 0.7

71 ± 2.1

1.15 ± 0.50

97 ± 3.0

125 ± 4.4

0.71 ± 0.06

87 ± 8.1

89 ± 4.4

1.38 ± 0.79

97 ± 3.7

113 ± 2.7

1.44 ± 0.05

101 ± 3.5

127 ± 6.2

0.78 ± 0.39

89 ± 3.5

108 ± 3.8

0.75 ± 0.49

85 ± 7.5

113 ± 8.3

1.09 ± 0.23

98 ± 8.0

65 ± 8.2

1.06 ± 0.08

103 ± 1.3

58 ± 2.9

0.65 ± 0.28

100 ± 2.3

96 ± 3.6

1.52 ± 0.20

97 ± 3.5

57 ± 4.6

1.13 ± 0.30

Cys-less

T199C

G20C

Q21C

S22C

T23C

I24C

N25C

Y26C

T27C

S28C

I29C

Y30C
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Table 2.2 Continued
Receptor

Growth Arrest
Activity (%)a

β-galactosidase
Activity (%)b

101 ± 3.5

71 ± 2.1

1.49 ± 0.21

99 ± 1.3

117 ± 2.4

0.88 ± 0.15

100 ± 4.0

61 ± 1.2

0.53 ± 0.13

Relative Kdc

G31C
N32C
G33C

a

Relative growth arrest activity (halo size ±standard deviation) was compared to that of the Cys-

less receptor at 0.5 μg of α-factor applied to a disk (the halo size of Cys-less was 23mm).
b

Relative β-galactosidase activity (±standard deviation) was compared with that of Cys-less at 1

μM α-factor.
c

The Kd values (±standard deviation) are presented relative to those of the Cys-less receptor.

The Kd was determined by saturation binding of radioactive α-factor according to the protocol
described in experimental procedures. (Kd of Cys-less receptor was 10.8 nM).
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Accessibility of N-terminal Cys residues
The substituted cysteine accessibility method (SCAM) has proven to be an important means to
determine the accessibility of residues as well as to gain knowledge about the secondary
structure of transmembrane proteins. SCAM was performed in order to uncover the solvent
accessibility of a portion of the N-terminus previously predicted to have secondary structure. For
SCAM we used MTSEA-biotin, a thiol-specific, membrane-impermeable reagent. To ensure that
the topology of the receptor was not perturbed by membrane preparation, whole cells were used
instead of isolated membranes as in previous SCAM experiments in our laboratory which probed
the first extracellular domain of Ste2p (14). The receptors T199C and Y266C were used as
accessibility controls as they were shown to be fully accessible (T199C) and inaccessible
(Y266C) to MTSEA-Biotin in previous studies (14, 35). Representative examples of
immunoblots are shown in Figure 2.2. As shown in all panels, no detectable labeling was
observed in the Cys-less and Y266C receptors but strong labeling was observed in T199C as
had been reported previously. However, substantial variation in the labeling of the mutants
was observed. Since cell surface expression of each mutant was different, the labeling of each
mutant was normalized to its cell surface expression to determine accessibility. This was done to
ensure that the solvent accessibility was not affected by the differential surface expression.
Finally, accessibility of each mutant was normalized to that of T199C, which was assigned as the
positive control for accessibility (100% labeling by MTSEA-biotin) (Table 2.3).
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Figure 2.2. MTSEA labeling of the N-terminal residues of Ste2p. Ste2p Cys mutants at
positions G20-G33 were labeled with MTSEA as described under Methods. T199C was
used as a positive control, and Y266C and Cys-less receptors were used as negative
controls. Molecular mass markers (kDa) are indicated on the left-hand side of the Fig. The
bottom panel shows overexposed immunoblots of the top panels.
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Table 2.3. Relative MTSEA-biotin labeling of Cys-scanned mutants of Ste2p

a

Receptor

Labelinga

T199C

1.00 ± 0.15

Y266C

0

Cys-less

0

G20C

0.09 ± 0.06

Q21C

2.19 ± 0.05

S22C

0

T23C

0.32 ± 0.02

I24C

0

N25C

0.19 ± 0.04

Y26C

0

T27C

1.08 ± 0.02

S28C

0

I29C

2.00 ± 0.20

Y30C

0.71 ± 0.02

G31C

1.30 ± 0.03

N32C

0.61 ± 0.04

G33C

1.19 ± 0.06

MTSEA-biotin labeling was adjusted to the surface expression of each mutant and normalized

to the labeling of T199C as calculated as {(Band intensity of mutant/Bamx of mutant)×Bmax of
T199C/Band intensity of T199C)}.
68

Examination of normalized accessibilities revealed that the residues in the target region
are not equally solvent accessible despite the fact that the N-terminus of Ste2p is extracellular;
residues in this region are expected to be equally solvent accessible. We found that four residues
(S22C, I24C, Y26C and S28C) were not detectably labeled (even when the gels were
overexposed, Figure 2.2 bottom). G20C, T23C and N25C were poorly labeled (<40%) and all of
the other residues in this targeted region (Q21C, T27C, I29C, Y30, G31, N32, and G33) were
labeled to 60% or more of the positive control. The amount of accessibility varied from ~5-fold
less (N25C) to ~2-fold higher (Q21C and I29C) as compared to T199C (Table 2.3). Many
mutants exhibited a lack of correlation between the surface expression and the solvent
accessibility. For example, residues I24C and N32C have similar surface expression (75% and
76%, respectively) as compared to the Cys-less, receptor (Table 2.1) but their accessibility is
entirely different, i.e., N32C is highly accessible but I24C is completely inaccessible.
The periodicity of accessibility from S22 to S28 in the N-terminus with residues S22, I24,
Y26, and S28 showing no apparent accessibility and residues Q21, T23, N25, T27, and I29
demonstrating accessibility would be consistent with that region of the N-terminus forming a strand structure as predicted in previous studies (28, 29) with one face of the -strand being
shielded from solvent. One explanation for the solvent inaccessibility would be involvement of
that portion of the N-terminus in a dimer interface. Previous studies have shown that deletion of
the first 45 residues of the N-terminus decreased dimerization of Ste2p (36). Thus we explored
the involvement of these -strand residues in Ste2p dimerization.
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Involvement of specific N-terminal residues in dimer formation
Cells expressing each of the different Cys mutants were grown and membranes were prepared.
The samples were analyzed by SDS-PAGE in non-reducing conditions and probed with antiFLAG™ antibody. A small dimer band at ~110 kD was observed with the Cys-less Ste2p and all
of the Ste2p Cys mutants under non-reducing (Figure 2.3A) and reducing conditions (Figure
2.1). This “SDS-resistant” band has been observed consistently in studies of Ste2p (29, 33, 37,
38). Under the non-reducing conditions (Figure 2.3A) there was an increase in the
dimer/monomer for many of the mutants. For example in Fig. 1 under reducing conditions I24C
is mostly in the monomeric form whereas in non-reducing conditions (Figure 2.3A) it is mostly
dimeric. We attribute the increased dimers to disulfide formation between the Cys-substituted
residues in the N-terminus as evidenced by the reversal of dimer formation by NEM pretreatment
(compare Figure 2.3B & Figure 2.3E) and by the lower dimer/monomer ratio under reducing
conditions (Figure 2.1). Under non-reducing conditions and in the absence of a catalyst, whereas
the majority species was monomeric in the Cys-less and the Q21C, T23C, N25C, T27C, I29C,
G31C, N32C, and G33C receptors, the G20C, S22C, I24C, Y26C, S28C, and Y30C receptors
were mostly in the dimer form (Figure 2.3A). In previous studies, we have shown that Cys crosslinking of Ste2p transmembrane domains and intracellular residues was promoted by Cu-P
(Cu(II)-1,10-phenanthroline) treatment. Cu-P treatment provides a more oxidative environment
and has been used in many experiments to determine Cys-Cys disulfide formation in membrane
proteins (39-43). With Cu-P treatment, many of the six Cys mutants (G20C, S22C, I24C, Y26C,
S28C, and Y30C) that showed a high dimer formation under non-reducing conditions (Figure
2.3A) exhibited an even higher dimer population (Figure 2.3B). In addition, in the presence of
Cu-P three mutants (N25C, T27C, and I29C), which did not form a significant proportion of
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dimer under non-reducing conditions, showed increased dimerization (compare Figure 2.3A and
Figure 2.3B). Dimer formation in the other mutants (Q21C, T23C, G31C, N32C, and G33C) was
not affected to a major extent by Cu-P treatment. To verify that the Cu-P stimulated increase in
higher molecular weight band was due to disulfide bond formation, samples were treated with
NEM (N-ethylmaleimide) prior to Cu-P addition. NEM alkylates the free −SH group of cysteine
irreversibly, so that disulfide bond formation cannot occur after NEM treatment. Representative
data for five mutants (N25C to I29C) are shown in Figure 2.3E. NEM pre-treatment was found to
block Cu-P stimulated dimerization for mutants N25C, T27C, and I29C (compare Figure 2.3B
and Figure 2.3E).
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Figure 2.3. Dimer formation by the Ste2p N-terminal Cysteine mutants. Membrane
proteins untreated (A), treated with Cu-P (B), incubated with α-factor followed by Cu-P
(C), incubated with antagonist followed by Cu-P (D) or NEM added prior to Cu-P (E) were
separated by SDS-PAGE, then immunoblotted and probed with anti-FLAG™ antibody.
The upper band (~110 kDa) represents dimerized receptor (indicated by “D”) and the
lower band (~55 kDa) represents monomer (indicated by “M”).
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Effect of ligand binding on dimerization

It has been observed that ligand binding can induce a change in a GPCR dimer interface (44,
45). To examine the effect of ligand on Cys-mediated dimerization, membranes were incubated
with either α-factor (agonist) or [desW1desH2]α-factor (an antagonist) prior to Cu-P treatment.
Notable reduction was observed in dimer formation for the N25C, T27C, and I29C mutants in
the presence of α-factor (compare Figure 2.3B to Figure 2.3C). In contrast, dimerization of
receptors with Cys in the other residues of this region was not greatly affected by agonist
binding. In addition, Cu-P stimulated dimerization was not affected significantly by antagonist
treatment for the mutants analyzed (compare Figure 2.3B and Figure 2.3D).
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Discussion
Binding of ligand to its cognate GPCR induces conformational changes in the receptor
which promote signal transduction across the membrane and activate a G-protein mediated signal
transduction cascade (46, 47). Ste2p, the α-factor pheromone receptor, is a GPCR expressed in
the yeast Saccharomyces cerevisiae and has been used extensively as a model for peptideresponsive GPCRs (48-50). Although Ste2p does not share sequence similarity with mammalian
GPCRs or even with Ste3p, the a-factor pheromone receptor of yeast, all GPCRs have the same
overall membrane architecture and manifest functional similarities such as G-protein coupling.
The extracellular N-termini of GPCRs are highly variable differing greatly in length and
sequence. Even within subfamilies, the N-termini often show low sequence homology. However,
recent studies have indicated that the N-terminal regions of GPCRs play important roles in
receptor function. For example, the N-terminus of several GPCRs has been found to be involved
in ligand binding (51-53), and receptor dimerization (36, 54), and cell surface targeting (55).
For Ste2p, extensive structure and function studies have been conducted on the
intracellular domains and transmembrane domains, while fewer studies have focused on the
extracellular N-terminal region. In those studies where this portion of Ste2p was studied, the role
of the N-terminus in glycosylation (56), dimerization (36) and mating (28, 29) was examined.
The Ste2p N-terminus is 48 amino acids long, and residues N25 and N32 are sites of N-linked
glycosylation (56). Nevertheless, removal of these glycosylation sites still resulted in a fully
active receptor (56). Deletion of the N-terminal 45 residues yielded a receptor that was deficient
in dimer formation (36), and deletion of the first 30 amino acids of the N-terminus of Ste2p
resulted in a cell that could not mate and showed weak signaling after pheromone addition (28).
In another study, 17 residues in the N-terminus (P15, P19, T23 to I36 and, N46) were
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investigated by substituting with Cys and Ala. This study showed that none of the substitutions
affected signaling, but mutation of residues P15, I24 and I29 greatly lowered the mating ability
of the cells carrying these mutations (29).
In this study we have explored the solvent accessibility and involvement in dimer
formation of a portion of the N-terminus of Ste2p to gain insights into the structure and function
of this domain of the receptor. SCAM has been used previously to study the lining of pores of
channels and transport proteins (57-59) and the binding site of acetylcholine receptors (60). More
recently, this method has been applied to study G protein-coupled receptors (14, 15, 27, 61-64).
Previous studies had suggested that certain residues in the N-terminus of Ste2p were critical for
pheromone induced mating but not for G1 arrest. Marsh and co-workers using S. cerevisiae/S.
kluyveri chimeras concluded that residues 1-45 were not involved in pheromone binding
specificity (65). Our binding studies on the Cys mutants of residues 20-33 of Ste2p would be
consistent with this observation. Despite the minor influence of the Cys mutations on receptor
signaling and pheromone binding here we report the first experimental evidence that all residues
in the N-terminus are not equally accessible and that the part of the N-terminus of Ste2p that
putatively contains a -strand participates in dimerization of Ste2p. Notably, we uncovered a
change in the conformation of the N-terminus upon agonist binding as determined by differences
in disulfide-mediated dimer formation in the active and inactive stages of Ste2p (Figure 2.3).
Our accessibility analyses showed that there were striking variations in the solvent
exposure of residues in the region of the N-terminus between residues S22 and S28. Residues
S22C, I24C, Y26C, and S28C were completely inaccessible to a membrane-impermeable,
hydrophilic, thiol-specific reagent MTSEA-biotin even though I24C and S28C receptors were
expressed at the cell surface as well as, or nearly as well as residues (Q21C, T27C, N32C, and
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G33C) whose Cys residues were accessible to MTSEA-biotin (Table 2.1 and Table 2.3).
Residues adjacent to the inaccessible residues readily reacted with the reagent. The differential
labeling of residues G20-S33 of the N-terminal residues is surprising since all these extracellular
residues were expected to be readily solvent accessible. The alternating pattern of accessibility of
consecutive engineered cysteines suggests an underlying structure of this region which is
consistent with predicted -strand spanning from Thr 23 to Tyr 30 (28, 29).
Based on the above SCAM analysis we hypothesized that the putative -strand in the Nterminus of Ste2p may be involved in dimerization of Ste2p, as the N-terminus of Ste2p had
been shown previously to be part of the Ste2p dimer interface (36). Indeed, our results show that
the cysteine-substituted residues S22, I24, Y26 and S28, which were not solvent accessible as
judged by disulfide crosslinking to a biotinylation reagent, were involved in dimer formation. On
the other hand, residues (Q21C, T23C, N25C, T27C, I29C) which would be on the opposite face
of the -strand and thereby accessible to biotinylation were not involved in dimer formation
under non-reducing conditions. Dimerization of the S28C mutant was blocked by NEM pretreatment (Figure 2.3E) corroborating the fact that dimerization was mediated by disulfide crosslinking of two nearby Cys residues. Disulfide bond formation suggests that the α-carbons of the
two Cys residues are located close to each other, within 7Å as the maximum distance, in order to
result in a disulfide bond (33, 66-68). Our modeling shows that disulfide formation between
residues in the N-terminus the putative -strand region would require a parallel arrangement of
two Ste2p molecules. In contrast to our results, previous studies indicated that residue I24C was
accessible in a SCAM experiment (29). The different outcomes between our and the previous
investigation may reflect differences in the assay conditions used. In our assay, labeling
experiments were performed with MTSEA-biotin using intact cells, whereas Shi and co-workers
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used isolated membranes and fluorescein-5-maleimide. We have observed that accessibility was
found to differ in experiments performed on isolated membranes versus whole cells in a study of
Ste2p EL1 residues (14).
Our results also demonstrate that agonist-induced conformational changes occur in the Nterminus of Ste2p as indicated by -factor induced changes in the Cu-P catalyzed oxidation of
dimerization for the N25C, T27C, and I29C mutants (compare Figure 2.3B and Figure 2.3CC).
However, treatment with antagonist, which binds but does not activate the receptor, did not
prevent the Cu-P-mediated increase in dimerization (compare Figure 2.3B, Figure 2.3C and
Figure 2.3D). We postulate that the conformation of the N-terminus changes in the active state of
the receptor such that the distance between these residues is too great for Cu-P induced disulfide
bond formation. In contrast, the residues involved in dimer formation in the non-reducing
conditions (22, 24, 26, and 28) still form a dimer interface in the activated state of the receptor.
For these interactions between receptor monomers to occur, the parallel -strands must have
enough flexibility to allow formation of disulfide bonds with residues on both faces of the strands as observed with Cu-P in the absence of alpha-factor.
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Conclusion
In conclusion SCAM analysis and disulfide crosslinking clearly show that in a short
segment of the N-terminus of Ste2p certain residues do not react with a soluble biotinylation
reagent and appear to be involved in receptor dimerization. The accessibility pattern, in
particular, is consistent with a stretch of -sheet-like structure involving residues G20-Y30.
Based on oxidative disulfide crosslinking studies, the dimer interface of the receptor changes in
response to pheromone indicating a change in conformation of the N-terminus of the receptor
during receptor activation. These studies provide evidence that the N-terminus of Ste2p
possesses a discrete structural domain that appears to participate in the signaling mechanism.
Information on the extracellular surface of other GPCRs should be useful in designing agents
that can modulate signaling and thereby influence cell physiology. The methods applied to Ste2p
should be applicable, therefore, to mammalian G protein-coupled receptors.
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Chapter 3
The N-terminus of Saccharomyces cerevisiae G protein-coupled
receptor Ste2p is involved in negative regulation

89

Abstract
Yeast pheromone receptor Ste2p is a G protein-coupled receptor that initiates cellular responses
to α-mating pheromone, a 13-residue peptide. We have examined the role of the extracellular Nterminus of this receptor in signal transduction. Sequential deletion of the N-terminal residues
affected cell surface expression without affecting ligand-binding affinity suggesting that the Nterminus is required for efficient cell surface targeting. Deletion of portions of the N-terminus
was found to affect signaling activity as determined by quantitative FUS1-LacZ gene reporter
induction assay. However, when the receptor surface expression levels of deletion mutants were
taken into account, the signaling activity was found to increase. This provides evidence that the
N-terminus of Ste2p is involved in the negative regulation of receptor signaling.
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Introduction
Signal transduction is a fundamental biological process that is essential to maintain
cellular homeostasis and processes in all organisms. The cells’ membrane proteins at the cell
surface communicate between the extracellular and intracellular environments of the cell and
respond accordingly to maintain cellular function. G protein-coupled receptors (GPCRs)
represent one of the largest families of plasma membrane receptors in eukaryotes. More than 800
GPCRs are encoded in the human genomes (1,2). These receptors play central roles in human
physiology and thus modifications in the signaling of these receptors are pertinent for many
diseases or pathological conditions including cardiovascular and pulmonary diseases, pain
perception, obesity, cancer, and neurological disorders. (3-5)
GPCRs share a common structural organization with an extracellular N-terminus, seven
transmembrane domains connected by extracellular and intracellular loops, and a cytoplasmic Cterminus (6,7). Despite the diversity of their ligands and a lack of strong sequence similarity, the
underlying mechanisms of signal transduction are similar as GPCRs couple the binding of
ligands to the activation of specific heterotrimeric guanine nucleotide-binding proteins (G
proteins) and/or non-G protein mediated signaling, leading to the modulation of downstream
effector proteins and gene expression (8-10).
The GPCR superfamily of receptors is divided into several subgroups on the basis of
phylogenetic criteria, conserved residues within the transmembrane helices and according to the
size and characteristics of the N-terminal domain of its members. Historically, the bulk of
attention of GPCR studies have focused on the transmembrane helices. However, a number of
studies indicate that the N-terminus also plays an important role in receptor function (6,11,12). A
conserved N-terminal cysteine network in class B secretin receptors stabilizes their structure, the
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alteration of which impairs ligand interactions (13). Likewise, a diverse variety of N-terminal
domain motifs in the N-terminal domain of class B adhesion receptors determine ligand
specificity. The conserved N-terminal Venus flytrap domain in Class C glutamate receptors and
N-terminal Wnt-binding domains in Frizzled/Smoothened receptors have been reported to
regulate ligand binding and receptor activation (6,11,12,14). The N-terminal domain of proteaseactivated receptors (PARs) and glycoprotein hormone receptors (GpHRs) plays an important role
in their activation (15,16). Recently, the N-terminus of GPR56, an adhesion G protein-coupled
receptor that plays a key role in cortical development, has been reported to constrain receptor
activity (17). Truncation of the N-terminus of several GPCRs including CB1 cannabinoid (18),
α1D adrenergic (19) and GPR37 (20) has been shown to enhance cell surface expression.
Here we investigate the function of the N-terminus of the α-factor pheromone receptor
Ste2p of Saccharomyces cerevisiae, which has been studied as a model for peptide-responsive
GPCRs (21,22). Although there has been considerable study of the extracellular and intracellular
loops as well as the C-terminus and transmembrane domains of Ste2p, less is known about the
role of the N-terminal domain in signaling. The N-terminus of Ste2p is ~48 amino acids long,
and it harbors two glycosylation sites (N25 and N32) which were eliminated by mutation (N25A
and N32A) without affecting receptor function (23). Other studies indicated that the N-terminus
contributed to receptor dimerization(24,25), and three residues (Pro 15, Ile24, and Ile29) were
found to be essential for mating but not for signaling as measured by growth arrest and reporter
gene (FUS1) activation assays (26). Truncation of parts of the N-terminus implicated this domain
in cellular fusion (mating) during late stages of conjugation of opposite mating types (26). We
performed deletion mutagenesis on the N-terminus and analyzed the mutant receptors by protein
expression, ligand binding, and signaling assays. The results showed that deletion of the N-
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terminus affected the surface expression levels of the receptor and results in enhanced signaling
activities of the receptor, suggesting that the N-terminus is involved in negative regulation of
signaling.
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Methods
Media, Reagents, Strains, and Plasmids: S. cerevisiae strain LM102 [MATa ste2 FUS1lacZ::URA3 bar1 ura3 leu2 his4 trp1 met1] (27) was used for growth arrest, FUS1-lacZ gene
induction, mating and saturation binding assays, and the protease-deficient strain BJS21 [MATa,
prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (8) was used for protein isolation to
decrease receptor degradation during immunoblot analyses (28). S. cerevisiae strain DK102
[MATa, Ste2::HIS3, bar1 ade2, trp1, ura3, his, leu2, lys2] (29) was used for expression of the
receptor under the control of Cu-inducible promoter CUP1. The plasmid pBEC2 containing Cterminal FLAG™ and His-tagged STE2 (30) was transformed by the method of Geitz (31). The
construction of pCUP1-BEC2 for expression of the C-terminal FLAGTM-His-tagged STE2 under
the CUP1 promoter was done by inserting CUP1 from plasmid pmCUPNMsGFPX (32) as the
promoter of STE2. Yeast transformants were selected by growth on yeast minimal medium (33)
lacking tryptophan and supplemented with casamino acids (10g/L, Research Products
International Corp., Prospect, IL.) designated as MLT to maintain selection for the plasmid. The
cells were cultured in MLT and grown to mid log phase at 30°C with shaking (200 rpm) for all
assays. S. cerevisiae strain TBR1 [MATα FLO11 ura3 his2 leu2] (34) was used the opposite
mating type (LM102 MATa) for mating assays. [Lys7 (7-nitrobenz-2-oxa-1,3-diazol-4yl),Nle12]α-factor abbreviated as [K7(NBD),Nle12]α-factor was synthesized as previously
described (35).

Growth Arrest Assays: S. cerevisiae LM102 cells, expressing Cys-less Ste2p and single Cys
mutants, were grown at 30°C overnight in MLT, harvested, washed three times with water, and
resuspended at a final concentration of 5 × 106cells/mL (36). Cells (1 mL) were combined with
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3.5 mL of agar noble (1.1%) and poured as a top agar lawn onto a MLT medium agar plate.
Filter disks (BD, Franklin Lakes, NJ) impregnated with α-factor (4, 2, 1, 0.5, 0.25 µg/disk) were
placed on the top agar. The plates were incubated at 30°C for 24h and then observed for clear
halos around the disks. The experiment was repeated at least three times, and reported values
represent the mean of these tests. For determination of growth arrest at various receptor
expression levels, DK102 cells expressing receptors under the control of CUP1 promoter were
grown for 16 hrs at 30C in minimal media. Cells were mixed with various final concentrations of
CuSO4 and poured onto agar plates with minimal media.

FUS1-lacZ Gene Induction Assay: LM102 cells, expressing Cys-less Ste2p and single Cys
mutants, were grown at 30 ºC in selective media, harvested, washed three times with fresh media
and resuspended at a final concentration of 5 x 107 cells/mL. Cells (500 µl) were combined with
α-factor (final concentration of 1.0 μM; this concentration is expected to saturate all the receptors
on the surface) and incubated at 30ºC for 90 min. The cells were transferred to a 96-well flat
bottom plate (Corning Incorporated, Corning, NY) in triplicate, permeabilized with 0.5% Triton
X-100 in 25 mM PIPES buffer (pH 7.2) and then β-galactosidase assays were carried out using
fluorescein di-β-galactopyranoside (Molecular Probes, Inc., Eugene, OR) as a substrate as
described previously (8,37). The reaction mixtures were incubated at 37°C for 60 min and 1.0 M
Na2CO3 was added to stop the reaction. The fluorescence of the samples (excitation of 485 nm
and emission of 530 nm) was determined using a 96-well plate reader Synergy2 (BioTek
Instruments, Inc., Winooski, VT). The data were analyzed using Prism software (GraphPad
Prism version 5.03 for Windows, GraphPad Software, San Diego CA). The experiments were
repeated at least three times and reported values represent the mean of these tests. For FUS1-
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LacZ induction in DK102 cells expressing wild type Ste2p under the control of CUP1 promoter,
cells were grown overnight in minimal media containing adenine, histidine, tryptophan and
lysine in the presence of various concentrations of CuSO4 (0.1-200 µM) before incubation with
α-factor.
Whole cell radioligand binding experiments: Tritiated [3H] α-factor (9.33 Ci/mmol) prepared as
previously described previously (38) was used in saturation binding assays on whole cells. Cells
(LM102) expressing wild type or mutant Ste2p were harvested, washed 3 times with YM1 (39),
and adjusted to a final concentration of 3 × 107cells/mL. Cells (600 µL) were combined with 150
µL of ice-cold 5× binding medium (YM1 plus protease inhibitors [YM1i] (39) supplemented
with [3H]α-factor and incubated at room temperature for 30 min. The final concentration of
[3H]α-factor ranged from 0.5 × 10−10 to 1 × 10−6 M. Upon completion of the incubation interval,
200 µL aliquots of the cell-pheromone mixture were collected in triplicate on glass fiber filter
mats and washed for 5 seconds with phosphate buffered saline, pH 7.4 using the Standard Cell
Harvester (Skatron Instruments, Sterling, VA). Retained radioactivity on the filter was counted
by liquid scintillation spectroscopy. Cells lacking Ste2p were used as a nonspecific binding
control for the assays. Binding assays were repeated a minimum of three times, and similar
results were observed for each replicate. Specific binding for each mutant receptor was
calculated by subtracting the nonspecific values (radioactivity obtained from cells lacking
receptor) from those obtained for total binding. Specific binding data were analyzed by nonlinear
regression analysis for single-site binding using GraphPad Prism 5.04 (GraphPad Software, San
Diego, CA) to determine the Kd and Bmax values for each mutant receptor.
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Immunoblots: BJS21 cells, expressing wild type or the N-terminal deletion mutants of Ste2p
grown in MLT, were used to prepare total cell membranes isolated as previously described (39).
Protein concentration was determined by the BioRad protein assay (BioRad, Hercules, CA)(30),
and membranes were solubilized in sodium dodecyl sulfate (SDS) sample buffer (10% glycerol,
5% 2-mercaptoethanol, 1% SDS, 0.03% bromophenol blue, 62.5 mM Tris, pH 6.8). Proteins
were fractioned by SDS−PAGE (10% acrylamide with 5% stacking gel) along with pre-stained
Precision Plus protein standards (BioRad) and transferred to an ImmobilonTMP membrane
(Millipore Corp., Bedford, MA). The blot was probed with anti-FLAG™ M2 antibody
(Sigma/Aldrich Chemical, St. Louis, MO), and bands were visualized with the West Pico
chemiluminescent detection system (Pierce). The total intensity of all Ste2p bands in each
lane was determined using a ChemiDoc XRS photodocumentation system with Quantity
One one-dimensional analysis software (version 4.6.9, BioRad, Hercules, CA). Immunoblot
experiments were repeated at least three times and yielded similar results. Constitutivelyexpressed membrane protein Pma1p was used as a loading control as described previously (40)
using Pma1p antibody (Thermo Scientific, Rockford, IL).

Deglycosylation of Membrane Proteins: Total membrane proteins prepared as described above
were resuspended in sodium phosphate (50 mM, pH 7.5), supplemented with 500 units of
glycerol-free PNGase F (New England Biolabs, Inc., Beverly, MA), and incubated at 37 °C for 2
h. A negative control was run in parallel in which no enzyme was added prior to incubation at 37
°C. Upon termination of the incubation interval, the membranes were pelleted by centrifugation
(15,000 × g, 10 min), and the resulting pellet was dissolved in SDS sample buffer. The samples
were used for FLAG immunoblot analysis as described above.
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Quantitative Mating Assay: MATa cells expressing various Ste2p constructs and MATα cells
expressing wild type receptor were grown overnight at 30°C, harvested by centrifugation,
resuspended in fresh YEPD, and counted using a hemocytometer. MATa cells (2×106) were
mixed with MATα cells (1×107) in a final volume of 100 µL, incubated at 30°C for 5 hours,
washed three times with water and resuspended in a final volume of 1 ml water. Then 20 µL of
the cell suspension was plated on minimal media lacking lysine and tryptophan and containing
histidine and leucine and incubated for 2 days at 30°C. Diploid colonies formed on the plates
were counted and analyzed by using GraphPad Prism. This experiment was repeated at least
three times and the mating efficiency was expressed as a percentage of diploid colonies formed
by mating between the wild type MATa (LM102) and MATα (TBR1) strains.
Flow Cytometry: S. cerevisiae strain DK102 expressing wild type Ste2p under the control of
CUP1 promoter was grown for 16 hrs at 30C with various concentrations of CuSO4 and washed
three times with 15 mM sodium acetate buffer (pH 4.6) containing sodium azide. Cells were resuspended in the same buffer to a final concentration of 1.5×106 cells/ml. Cells (500 µl of the
suspension) were incubated with 1 µM final concentration of a fluorescent α-factor analogue
[K7(NBD),Nle12]α-factor for 30 minutes at room temperature with end-over-end mixing. The
cells were then washed three times with the same buffer containing sodium azide (10 mM) and
200 µl of this cell suspension were added into a well of a 96-well plate and analyzed on a EMD
Millipore (MA, USA) flow cytometer (Guava 6HT-2L) using excitation at 488 nm and emission
at 525/30 nm (as specified by the Guava instrument). The samples were protected from light
during pre-incubations and flow cytometry analysis. The mean fluorescence intensity obtained at
various concentrations of CuSO4 was used to calculate relative cell surface expression. The mean
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fluorescence data obtained from the Guava were analyzed by GraphPad Prism using non-linear
regression analysis.
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Results
The mutant receptors are expressed but differentially glycosylated:
To gain insight into the role of the N-terminus of the yeast α-factor receptor Ste2p in receptor
function, we set out to identify specific regions in the N-terminus that influence receptor function
(See Figure 3.1 for Ste2p snake diagram). For this purpose, we carried out deletion mutagenesis
of the region between residues S2 to Y30 generating five mutants [Ste2pΔ2-10, Ste2pΔ11-20,
Ste2pΔ21-30, Ste2pΔ2-20 and Ste2pΔ2-30 (Figure 3.2)] on the backbone of the full-length, Cysless receptor (Ste2p-C52S and C259S) with a His and FLAG tag extending from the C-terminus
of Ste2p that we refer to herein as the wild type (Figure 3.1). Previous studies have established
that this “wild-type” receptor was equivalent in expression and activity to the naturally occurring
wild-type Ste2p (25,30,41). All mutants as well as the wild type receptor were expressed from a
high copy yeast expression vector under the control of the constitutive GPD promoter (8,30).
To test the mutant receptor expression, total membranes were prepared from yeast
carrying each of the mutant constructs and the wild type control, the membrane proteins were
solubilized and run on SDS-PAGE, immunoblotted, and probed with FLAG™ antibody (Figure
3.3). As a loading control for immunoblot experiments, the same immunoblots were washed and
re-probed with antibody against the constitutively expressed membrane protein Pma1p. The
experiment was repeated at least three times with similar results obtained in each experiment.
Wild type Ste2p (Lane 2) appeared as a set of three major bands between 50 and 55 kDa, plus
small amounts of higher molecular weight dimers (~100 kD) and oligomers, as observed in many
previous studies, for example (30,42,43). Based on the primary amino acid sequence of the
FLAG- and His-tagged receptor construct used in this study, the predicted molecular mass is
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50.8 kDa (30). Glycosylation of the protein has been shown to result in the disparity of molecular
weights of the Ste2p monomer (23,30,44,45).

Figure 3.1. Diagram of Ste2p. The transmembrane domains are shown between the two
parallel lines indicating the leaflets of the lipid bilayer. The intracellular and extracellular
boundaries for the transmembrane domains are based on information obtained by SCAM
analysis as reported previously (46). The receptor residues are numbered from the N
terminus (residue 1) to the C terminus (residue 458) and include the inserted FLAG and
His epitope tags (residues 432– 439 and 450 – 455, respectively), and spacer residues
between the FLAG and His tags in the C-terminal portion. The two endogenous Cys
residues mutated to Ser to generate the Cys-less Ste2p background are indicated by crosshatching in TM1 and TM6.
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Figure 3.2. Schematic representation of the Ste2p mutants analyzed in this study. Each
mutant is designated by the residue numbers deleted from the N-terminus and shown by
the Δ symbol in the Fig. The upper line depicts the amino acid sequence for the N-terminal
domain (box with amino acid sequence) and the seven transmembrane domains along with
the C-terminal domain is indicated in black shades, not to scale. The potential glycosylation
sites (N25 and N32) are indicated by the symbol Ψ. For each deletion mutation, the
remaining Ste2p sequence is indicated (box with letters). The deleted sequence is indicated
by empty box
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Figure 3.3. Ste2p total expression levels. Proteins were solubilized from total membranes (5
µg) prepared from cells expressing various N-terminal deletion mutants (Ste2pΔ2-10,
Ste2pΔ2-20, Ste2pΔ2-30, Ste2pΔ11-20, Ste2pΔ21-30) and the wild type receptor and run on
a SDS-PAGE gel and immunoblotted using antibody against the C-terminal FLAG™
epitope tag. M and D indicate the monomeric and dimeric forms of Ste2p, respectively.
Molecular mass markers (kDa) are indicated on the left-hand side. The same blot was
stripped and then re-probed with anti-Pma1p antibody as a loading control.
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The expression level of each mutant receptor in the total membrane preparation was
determined from the FLAG-reactive bands in each lane (monomer, dimer, and higher molecular
weight bands), the loading in each lane was normalized to the Pma1p control, and then the
expression levels were compared to the wild type receptor, the wild type receptor expression
level was considered 100%). The total membrane expression levels were found to range from
54% (Ste2pΔ2-30) to 81% (Ste2pΔ11-20) of the wild type.
In addition to the reduced levels of expression, the mutants Ste2pΔ2-20, Ste2pΔ2-30,
Ste2pΔ11-20, and Ste2pΔ21-30 exhibited altered banding patterns as compared with the wild
type (Figure 3.3; Figure 3.4 lanes designated by C). We postulated that the different banding
patterns were due to differential glycosylation of the mutant receptors as the two glycosylation
sites of the receptor (N25 and N32) are located either within or adjacent to the deletion sites. To
test this assumption, membranes were prepared from the mutants as well as the wild type cells,
treated with PNGase F at 37°C to deglycosylate the receptor, and the banding pattern was
examined. The higher molecular weight forms (greater than 130Kda) of Ste2p are attributable to
receptor aggregation as a result of the incubation of the sample at 37°C for 2 hours which are
conditions necessary for the deglycosylation reaction [Figure 3.4, Lanes (-) and Lanes (+)]. The
aggregation of the receptor is likely responsible for the significant reduction in the overall
intensity of the Ste2p monomer band after the treatment (Compare lanes C and _ or + in Figure
3.4). Such temperature-dependent aggregation has been observed previously by our lab (30). The
results indicated that the variability in the number of bands was diminished after PNGaseF
treatment with most receptors exhibiting a prominent single band and the aforementioned high
MW aggregate near the top of the gel (except Ste2pΔ2-30 which was not glycosylated) (Figure
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3.4). The collapse of the multiple bands at 50-55 kDa into one major band at about 50 kDa after
PNGaseF treatment has been reported previously (23,30).
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Table 3.1. Total expression, surface expression and binding affinity of Ste2p N-terminal
deletion mutants
Receptors

Relative total expression

Relative Bmaxb

Relative Kdc

levelsa
Wild type

1.00 ± 0.07

1.00 ± 0.08

1.00 ± 0.16

Ste2pΔ2-10

0.79 ± 0.08

0.89 ± 0.07

1.33 ± 0.22

Ste2pΔ2-20

0.62 ± 0.06

0.31 ± 0.02

1.18 ± 0.17

Ste2pΔ11-20

0.81 ± 0.07

0.26 ± 0.03

0.93 ± 0.22

Ste2pΔ21-30

0.56 ± 0.06

0.17 ± 0.03

1.48 ± 0.49

Ste2pΔ2-30

0.54 ± 0.05

0.09 ± 0.01

1.00 ± 0.23

a

Relative total expression level (±SEM) of the N-terminal deletion mutants of Ste2p. Ste2p band

intensity was quantitated by Quantity One software (BioRad) and normalized to the Pma1p band
intensity (for protein loading on the gel) and the Cys-less wild type receptor. Expression level of
each receptor was calculated as
{
b

}

{

}

Relative surface expression (±SEM) of N-terminal deletion mutants of Ste2p. Surface

expression was determined by saturation binding assay using tritiated [3H] α-factor with whole
cells. The relative surface expression was expressed as
c

The Kd values (±SEM) are presented relative to those of the Cys-less wild type receptor. The Kd

was determined by saturation binding of radioactive α-factor according to the protocol described
in experimental procedures. (Kd of wild type receptor was 21.93 nM).
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Figure 3.4. Deglycosylation of N-terminal deletion mutants of Ste2p. Total membrane
proteins derived from cells expressing wild-type or deletion mutant receptors indicated
were treated (+) with PNGase F as described under “Experimental Procedures” or
incubated in parallel in the absence of enzyme (-) to control for degradation or aggregation
which might occur as a result of exposure to elevated temperature. The proteins were then
analyzed by immunoblot analysis using the anti-FLAG antibody. In control lanes (C)
membrane proteins were solubilized directly into denaturing sample buffer immediately
prior to SDS-PAGE and subsequent immunoblot analysis. Molecular mass markers (kDa)
are indicated on the left-hand side of each panel. The prominent bands visible at ∼50 kDa
corresponds to the monomeric forms of glycosylated Ste2p, whereas deglycosylated
receptor (Ste2p, degly-M) appears as a band of reduced molecular weight.
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The N-terminus is important for efficient surface expression but not required for ligandbinding:
The immunoblot analysis measured total receptor expression in the membrane fraction,
but it did not provide information regarding receptor expression on the cell surface.
Consequently, the surface expression of the mutants was determined by whole cell saturation
binding assays using [3H]α-factor as described previously (39,41,47). The Bmax values from the
saturation binding curves (Figure 3.5) were used to calculate the number of receptors on the cell
surface (47).The surface expression level of Ste2pΔ2-10 was approximately 90% of the wild
type, but the surface expression levels of the other mutants were significantly lower (p= 0.05)
and varied between 9% (Ste2pΔ2-30) and 31% (Ste2pΔ2-20) of the wild type (Table 3.1). These
results indicate that receptors with N-terminal deletions are well expressed as judged by total
expression levels but they exhibited reduced cell surface expression. The involvement of the Nterminus in surface expression is consistent with our previous study (25) and those of others
(48,49).
The binding affinities of the receptors as determined by whole cell saturation binding
assays (30,39) were not significantly different (p= 0.05) from the wild type receptor (Table 3.1).
These results indicated that the N-terminus was not directly involved in ligand binding and did
not influence the formation of the ligand-binding pocket which is consistent with the observation
by Sen and Marsh that the N-terminus of Ste2p was not involved in determining ligand
specificity (50).
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Figure 3.5. Saturation binding of [3H]α factor to various N-terminally deleted Ste2p. Whole
cell saturation binding assay of [3H]α-factor to wild type Ste2p and N-terminal deletion
mutants were determined. From these saturation curves the binding affinities were
determined by nonlinear regression analysis using GraphPad Prism. The data represent
specific binding to cells as determined by subtracting the binding to an isogenic strain
lacking the receptor from binding to cells containing wild type or mutant Ste2p.

Deletion of portions of the N-terminal enhanced pheromone-induced signaling activity:
To investigate the role of the N-terminus in signaling activities, we examined the mutant
receptors by pheromone-induced growth arrest and FUS1-LacZ induction assays as well as
quantitative mating assays. The growth arrest assay measures the response of cells expressing
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Ste2p to arrest growth at the G1 phase based on the size of halos surrounding disks impregnated
with various amounts of pheromone applied to lawn of pheromone-responsive cells. This assay
measures response over a 24 to 48 h time frame. The FUS1-LacZ induction assay measures an
early response (1 to 2 h) of the yeast cells to pheromone as detected by induction of βgalactosidase activity through a reporter gene construct consisting of a fusion between FUS1, a
pheromone-responsive promoter, and the LacZ gene (51). Mating assays measure the ability of
the cells to conjugate with cells of the opposite mating type producing diploid cells. The number
of diploid colonies formed as a result of mating between the two mating types can be compared
to that of the wild type indicating mating efficiency. The signaling responses of the mutants in
each experiment were normalized to those of the wild type (Figures 3.6, 3.7, 3.8 and Table 3.2).
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Figure 3.6. (A) Growth arrest (halo) assays of wild type and deletion mutant receptors.
Cells containing wild type Ste2p or cells with N-terminally truncated Ste2p were plated
onto medium. Disks containing α-factor (4.0, 2.0, 1.0, 0.5, and 0.25 µg/disk, starting at the
12 O’clock position on each plate and moving clockwise) were placed onto the lawn of cells.
The plates were incubated for 48−72 h at 30°C: a) wild type, b) Ste2pΔ2-10, c) Ste2pΔ11-20
d) Ste2pΔ21-30 e) Ste2pΔ2-20, f) Ste2pΔ2-30. (B) Halo size produced by the wild type and
various mutants at 1.0 µg α-factor was compared.
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In growth arrest assays, the halo diameter produced by the same amount of ligand was
compared (Figure 3.6B & Table 3.2). The results showed that the growth arrest responses of the
mutants were nearly the same as those of the wild type, with the exception of Ste2pΔ2-30 which
had a 25% decrease in halo diameter compared to the wild type at 1.0 µg α-factor (Figure 3.6B).
Although the number of receptors on the cell surface of the mutants was different (Table 3.1),
the growth arrest activity of the mutants was similar with the exception of Ste2pΔ2-30.
Therefore, the growth arrest response in the N-terminal deletion mutants was not proportional to
the level of receptor expressed on the surface.
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Figure 3.7. (A). Pheromone-induced FUS1-LacZ induction. Dose-response curves for αfactor stimulated FUS1–lacZ induction of the N-terminal deletion mutants. Data are
expressed as a percentage of the maximal response stimulated by the full length wild type
receptor. (B). Maximal induction (%) is determined from the data on panel A with the
highest concentration of α-factor (1 µM). Results represent average from three
independent experiments performed in quadruplicate. One-way ANOVA followed by
Dunnett’s post hoc test was used to determine statistical significance (n = 4; p < 0.05).
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In FUS1-LacZ induction assays (Table 3.2 and Figure 3.7A) all mutant receptors
exhibited potencies (EC50 values) similar, not less than or greater than 30%, of that of wild type
receptor. Maximal responses produced by the mutants reflect efficacy (intrinsic activity) of the
receptors. In contrast, potency (EC50), the molar concentration of an agonist required to produce
50% of the maximal response to the agonist, reflects a complex function of both efficacy and
affinity. Therefore, increased maximal signaling by Ste2pΔ2-10 indicates that deletion of the
residues 2-10 in the N-terminus enhances the intrinsic signaling activity of the receptor. Also
constitutive signaling, as measured by gene reporter activity in the absence of added α-factor,
was the same as wild type for each receptor (data not shown). In contrast, the maximal signaling
activity or efficacy, (FUS1-LacZ expression obtained at 1×10-6 M α-factor) exhibited variation
among the receptors with signaling between 28% (Ste2pΔ2-30) and 152% (Ste2pΔ2-10) of the
wild type (Table 3.2 and Figure 3.7). Out of the five mutants tested, Ste2pΔ2-20, Ste2pΔ21-30,
and Ste2pΔ2-30 exhibited a significant decrease in signaling (p<0.05), Ste2pΔ11-20 exhibited
similar activity as the wild type and Ste2pΔ2-10 appeared to increase the signaling activity.
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Figure 3.8. (A). Auxotrophic MATα strain (TBR1 was mated with MATa STE2Δ yeast
strain (LM012) expressing wild type (a) Ste2pΔ2-10 (b), Ste2pΔ2-20 (c) Ste2pΔ21-30 (d),
Ste2pΔ11-20 (e) and Ste2pΔ2-30 (f). (B). Mating efficiency of the strains were analyzed and
compared to that of the wild type. Statistical significance was analyzed at p<0.001 by using
GraphPad Prism.
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The two mutants Ste2pΔ2-10 and Ste2pΔ11-20 exhibited enhanced mating efficiency
(p<0.001) (Figure 3.8). Statistical analyses revealed that the mating efficiency of the Ste2pΔ220, Ste2pΔ2-30, and Ste2pΔ21-30 was not significantly different from that of the wild type at
p<0.001.
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Table 3.2. Signaling activities of Ste2p mutants.
Receptors

a

Relative

Relative

EC50(nM)c

Maximal FUS1-LacZ

growth arrest

maximal FUS1-

induction/Surface

activitya

LacZ Inductionb

expressiond

Wild type

1.00 ± 0.05

1.00 ± 0.06

46 ±5

1.00 ± 0.06

Ste2pΔ2-10

1.02 ± 0.04

1.52 ± 0.01

32 ± 4

1.7 ± 0.08

Ste2pΔ2-20

0.96 ± 0.04

0.39 ± 0.03

56 ± 2

1.3± 0.07

Ste2pΔ11-20

1.06 ± 0.05

0.94 ± 0.04

36 ± 3

3.6± 0.30

Ste2pΔ21-30

0.95 ± 0.05

0.30 ± 0.01

44 ± 1

1.8 ± 0.18

Ste2pΔ2-30

0.72 ± 0.04

0.28 ± 0.02

48 ± 1

3.1 ± 0.20

Relative growth arrest activity (halo size ±SEM) was compared to that of the Cys-less wild type

receptor at 1.0 μg of α-factor applied to a disk (the halo size of the Cys-less wild type was
23mm).
b

Relative maximal FUS1-LacZ induction (±SEM) of each mutant was calculated with respect to

Cys–less wild type receptor when induced with the highest concentration of α-factor (1
µM).
c

Determined from FUS1–lacZ assays. EC50 (potency) reflects the concentration of α-factor

required to cause half–maximal induction.
d

Maximal FUS1-LacZ induction of each mutant was normalized to its surface expression level

and compared to that of the Cys-less wild type.
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We have shown that deletion of portions of the N-terminal tail of Ste2p decreased the
surface expression level of mutant receptors without any significant change in their binding
affinities (Table 3.1). Although surface expression of Ste2p has been found to affect signaling
activity as determined by FUS1-LacZ reporter assay (Figure 3.7), the calculated signaling
activities do not take into account the level of surface expression. Therefore, to compare the
signaling activities of the mutants based on the cell surface expression the maximal FUS1-LacZ
activation was normalized to the amount of receptor on the cell surface as determined by
saturation binding experiments. Interestingly, although the apparent signaling activity of the
mutants was weaker than that of the wild type, this normalization revealed that the maximum
FUS1-LacZ response of the mutants was in fact stronger than the wild type (Figure 3.9). We
observed that truncation of the N-terminus significantly enhanced the relative FUS1-LacZ
response by 2- to 3-fold. Thus, receptors lacking portions of the N-terminus are actually more
effective with respect to signaling than the wild type.
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Figure 3.9. Normalized FUS1-LacZ activity of each receptor construct as compared the
wild type. The maximal signaling activity of each construct was normalized to the number
of receptors expressed on the cell surface. One way ANOVA was carried out at p<0.05 to
determine statistical significance using GraphPad Prism
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In order to further evaluate the relationship of signaling to surface expression of various
Ste2ps, we ascertained the surface expression and signaling activity with the same wild type
receptor expressed at various levels. The wild type Ste2p was expressed under the control of
Copper-inducible promoter CUP1 from the URA3 based plasmid pCBEC2 (52). We performed
growth arrest and FUS1-LacZ assays to determine if there was any correlation between the
surface expression level and signaling activities. Relative surface expression levels at various
concentrations of CuSO4 was determined using a fluorescent α-factor analogue
[K7(NBD),Nle12]α-factor (35,53) by flow cytometer. We were able to regulate the surface
expression level of Ste2p in a dose-dependent manner such that incubation with increasing
concentrations of CuSO4 led to increasing the amount of [K7(NBD),Nle12]α-factor on the surface
as measured by mean fluorescence intensity (Figure 3.10). As judged from Figure 3.10B, there
was a large increase in the number of receptors at 50 M CuSO4.
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Figure 3.10. Receptor expression level at the cell surface determined by flow Cytometry. (Wild type Ste2p expressed under the
control of copper-inducible promoter at different concentrations of CuSO4. A) FACS histograms of cells expressing no
receptors (top panels) and wild type (bottom panels) in the presence of saturating concentration of the ligand. The
concentrations of CuSO4 (μM) were 0 (a), 5 (b), 10 (c), 20 (d), 50 (e) and 100 (f) B). The histograms represent the number of
cells (Y-axis) plotted against the fluorescence intensity (X-axis). The mean fluorescence intensity obtained from the histograms
(insert number, upper right hand corner of histograms) was analyzed using non-linear regression analysis in GraphPad
Prism.
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Growth arrest assay indicated that the halos were turbid with indistinct edges at lower
receptor expression levels. However, at higher expression levels, the halos were less turbid with
distinct edges (Figure 3.11A). The results indicated that halo size was similar at the various
concentrations of CuSO4 used in the experiment. The result is consistent with previous studies in
which it has been shown that halo size produced by cells with different receptor expression level
was similar (54). In FUS1-LacZ induction assays increasing signal was observed as the
concentration of CuSO4 increased (Figure 3.11B).
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Figure 3.11. Signaling activities of the wild type receptor expressed at different levels. (A)
Growth arrest assay at various concentrations of CuSO4 (μM): (a) 0 (No added CuSO4) (b)
0.2, (c) 0.5, (d) 1.0, (e) 2.0, (f) 5.0, (g) 10.0, (h) 20.0, (i) 50.0, (j) 100. (B) FUS1-LacZ
induction at different concentrations of CuSO4 (μM): 0 (no added CuSO4), 0.2, 0.5, 1.0, 2.0,
5.0, 10, 20, 50 and 100. Data from FUS1-LacZ assay were analyzed by non-linear regression
analysis using GraphPad Prism.

Detection of increase in FUS1-LacZ activity (Figure 3.11B) was more sensitive to lower
CuSO4 induction levels than was detection of surface expression of Ste2p (Figure 3.10A & B).
These results supported our hypothesis that signaling activity judged by the gene induction assay
is correlated to receptor expression levels, although this relationship is not clear at lower
expression levels due to the inability of flow cytometry to detect receptor expression above the
background level at CuSO4 levels below 20 µM.
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Discussion
The N-termini of several GPCRs have been reported to play roles in receptor function
such as constraining receptor activation (17) or acting as a tethered ligand (55). The N-terminus
of Ste2p was previously associated with dimerization (24,25,56), mating (26,57) and as a site for
glycosylation (23). Consistent with previous studies (49,50), we found that the N-terminus was
important for cell surface expression but not required for ligand binding. Our experiments on the
N-terminus indicated that deletion of N-terminal regions resulted in enhanced signaling as
analyzed by FUS1-LacZ assays when normalized to Ste2p surface expression.
It is generally assumed that the signaling activity of Ste2p is independent of receptor
expression level (45,58,59). This assumption was based on signaling activities determined by the
growth arrest assay and direct measurement of surface receptor expression level determined by a
binding assay (54). In addition, the Dumont group supported this conclusion based on their
analysis of the FUS1-LacZ assay (43). However, interpretation of the Gehret et al. (43)
experiments involving the signaling activity as determined by the FUS1-LacZ assay was
complicated by the fact that only the total expression, not the surface expression of Ste2p, was
evaluated for the two strains: Ste2p expressed from the normal chromosomal STE2 locus versus
Ste2p expressed under repressed condition from the GAL1 promoter (absence of galactose and
the presence of glucose). The interpretation is also complicated by the concerns that receptor
expression level on the cell surface and the number of G protein subunits available to interact
with the activated receptor can affect the signaling activity. It has been reported that the number
of G proteins is approximately equal to the number of receptors in cells containing normal
chromosomal copies of the genes encoding receptors and G protein subunits (60-62). Therefore,
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if the available G proteins are saturated with the receptors expressed on the surface, increasing
the expression level of Ste2p beyond the available of G proteins will not increase signaling.
The FUS1-LacZ reporter gene assay has been used as a quantitative assay for
measurement of pheromone-induced signaling through Ste2p and its mutants in numerous
studies (27,47,51,63,64). Our analyses with wild type receptor expressed under the control of a
copper-inducible promoter CUP1 demonstrated that signaling activity as measured by FUS1LacZ was dependent on the number of surface expressed receptors (Figure 3.10 & 3.11B). This
observation is consistent with the idea that the signaling activity as determined by the FUS1LacZ assay is dependent on the surface expression level of Ste2p. However, the signaling activity
as determined by growth arrest assay does not correlate to the level of expression at the levels of
copper used in the experiments (Figure 3.11). The difference in the two measurements of
signaling activities indicates that the long-term growth arrest assay is relatively less responsive to
the amount of receptor expressed at the cell surface. The apparent differences in the results of the
two assays may be a consequence of difference in the level of receptor expression in cells grown
in suspension versus cells grown on agar or the time frame of the assays.
Mutants that were found to exhibit the greatest reduction in cell surface expression
demonstrated marked changes in the banding pattern for Ste2p on SDS-PAGE (Figures 3.3 and
3.4). It is probable that the changes in the banding pattern were due to altered glycosylation of
the mutants because of either deletion of, or proximity to, the mutation of the two Ste2p
glycosylation sites at N25 and N32. Accordingly, deglycosylation of the receptors resulted in the
collapse of several bands into a major band which is consistent with previous studies in our lab
(30) and others (23). However, removal of the two glycosylation sites does not affect receptor
activity or subcellular localization (23). Thus reduced surface expression cannot be attributed
125

simply to changes in the glycosylation pattern of the receptors. It has been reported previously
that the charged residues in the N-terminus are important for proper orientation of the receptor in
the membrane (49). It is reasonable that a combination of the modification in the glycosylation
pattern and changes in the electrostatic properties of the N-terminus influence the localization of
Ste2p and its orientation in the plasma membrane.
Despite reduced surface expression and altered glycosylation, the mutant receptors were
still functional, i.e., they exhibited similar ligand binding affinity and responded to ligand
effectively in both growth arrest and gene induction assays. When the signaling activities of the
mutant Ste2ps were normalized to the number of receptors that bound α-factor, the mutants
actually exhibited a greater response than wild type. In fact the Ste2p11-20 and Ste2p2-30
mutants are more than 3-fold more effective than the full-length receptor in the signaling
efficacies as measured by the reporter gene assay. Nevertheless, the activity of the Ste2p2-20
receptor was similar to wild type receptor showing that regulation by the N-terminus governing
signaling response is complex and cannot be divided onto linear domains. Our control
experiments with wild type receptor at various expression levels support the conclusion that
maximal signaling activity as measured by gene reporter is dependent on receptor expression
levels on the cell surface.
For measurement of signaling activities, we used pheromone-induced growth arrest and
FUS1-lacZ assays. The growth arrest activities of the mutants were found to be similar to the
wild type with the exception of Ste2p∆2-30. The reduced signaling of Ste2p∆2-30 mutant may
be attributed to inefficient targeting to the membrane (49). However, this mutant construct still
binds the ligand efficiently and signals. This mutant was reported previously to exhibit weaker
growth arrest activity with indistinct halo edges as compared to ours (57). As shown in our
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control experiment with the wild type receptor, the fuzzy halo may result from poor expression
level on the cell surface (Figure 10A). The difference in the signaling activity by growth arrest
may also be attributed to the differences in strain background and promoter used in our study as
compared to that of Shi, et al. (57). We expressed the receptor from a constitutively active GPD
promoter while they used an inducible GAL1 promoter. Further examination of signaling
activities using a more sensitive, quantitative and shorter term reporter gene activation assay
(FUS1-LacZ) revealed that the signaling activity of the mutants was enhanced as compared to the
wild type when receptor expression levels at the cell surface are taken into account to normalize
signaling activities.
The results from the gene induction assay (Figure 3.9) indicate that the N-terminus of
Ste2p is involved in negative regulation of signaling activity by this GPCR. In fact, the Nterminus of another GPCR, GPR56, has been reported to constrain receptor activity (17). The Nterminus of GPR61, an orphan GPCR that is abundantly expressed in the brain, was also reported
to be essential for constitutive activity (65). Thus the results from our analysis of the role of the
N-terminus of Ste2p in its function, and those of others involving different mammalian GPCRs,
indicate an increasing importance for the N-terminus in the biology of GPCRs. Although the Nterminus may not be essential for GPCR signaling, its role in the regulation of signaling has been
ignored to some extent in previous studies. The N-terminus may be required for fine tuning the
signaling process and thus may be an important drug target for future drug design studies in
which the GPCR function can be regulated more specifically.

In order for the N-terminus to be involved in negative regulation of Ste2p signal
transduction, it is likely that the N-terminus interacts with receptor domains that are important
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for signal transduction. A secondary structure analysis suggested that regions of the N-terminus,
in particular residues 20-30, have a strong tendency to form β-sheet structures, (25,57). It is
possible that removal of portions of the N-terminal domain lowers either intramolecular
interactions within Ste2p or intermolecular contacts with other domains of the Ste2p dimer
(24,25). The sum of these β-sheet-like contacts may help to maintain the receptor in its inactive
conformation and their removal would thereby facilitate transition to an activated state upon
ligand binding. We speculate that the interacting domain with the N-terminus is the extracellular
loop one (EL1) as mutation of residues in this loop has been found to change the glycosylation
patterns of the receptor and its ability to be activated, and a structure prediction also indicates a
tendency to form sheet secondary structures (30,57). However, we do not exclude the possibility
of interactions with other Ste2p domains. Overall, this study demonstrates that important
information about receptor regulation can be obtained from the study of the N-terminus.

128

Acknowledgments
We thank Prof. Yury Chernoff, Georgia Tech University, for the pmCUPNMsGFPX plasmid as
the source of the CUP1 promoter. This research was supported by grant GM-22087 from the
National Institute of General Medical Sciences, NIH.

129

References

1.

Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., and Babu, M. M.
(2013) Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194

2.

Fredriksson, R., Lagerstrom, M. C., Lundin, L. G., and Schioth, H. B. (2003) The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis,
paralogon groups, and fingerprints. Molecular pharmacology 63, 1256-1272

3.

O'Hayre, M., Vazquez-Prado, J., Kufareva, I., Stawiski, E. W., Handel, T. M., Seshagiri, S., and
Gutkind, J. S. (2013) The emerging mutational landscape of G proteins and G-protein-coupled
receptors in cancer. Nature reviews. Cancer 13, 412-424

4.

Salon, J. A., Lodowski, D. T., and Palczewski, K. (2011) The significance of G protein-coupled
receptor crystallography for drug discovery. Pharmacological reviews 63, 901-937

5.

Kobilka, B. K. (2011) Structural insights into adrenergic receptor function and pharmacology.
Trends in pharmacological sciences 32, 213-218

6.

Kristiansen, K. (2004) Molecular mechanisms of ligand binding, signaling, and regulation within
the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches
to receptor structure and function. Pharmacology & therapeutics 103, 21-80

7.

Gether, U. (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled
receptors. Endocrine reviews 21, 90-113

8.

Umanah, G. K., Huang, L., Ding, F. X., Arshava, B., Farley, A. R., Link, A. J., Naider, F., and
Becker, J. M. (2010) Identification of residue-to-residue contact between a peptide ligand and its
G protein-coupled receptor using periodate-mediated dihydroxyphenylalanine cross-linking and
mass spectrometry. The Journal of biological chemistry 285, 39425-39436

130

9.

Eilers, M., Hornak, V., Smith, S. O., and Konopka, J. B. (2005) Comparison of class A and D G
protein-coupled receptors: common features in structure and activation. Biochemistry 44, 89598975

10.

Oldham, W. M., and Hamm, H. E. (2008) Heterotrimeric G protein activation by G-proteincoupled receptors. Nature reviews. Molecular cell biology 9, 60-71

11.

Kobilka, B. K. (2007) G protein coupled receptor structure and activation. Biochimica et
biophysica acta 1768, 794-807

12.

Lagerstrom, M. C., and Schioth, H. B. (2008) Structural diversity of G protein-coupled receptors
and significance for drug discovery. Nature reviews. Drug discovery 7, 339-357

13.

Beinborn, M. (2006) Class B GPCRs: a hidden agonist within? Molecular pharmacology 70, 1-4

14.

Ersoy, B. A., Pardo, L., Zhang, S., Thompson, D. A., Millhauser, G., Govaerts, C., and Vaisse, C.
(2012) Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR.
Nature chemical biology 8, 725-730

15.

Scarborough, R. M., Naughton, M. A., Teng, W., Hung, D. T., Rose, J., Vu, T. K., Wheaton, V.
I., Turck, C. W., and Coughlin, S. R. (1992) Tethered ligand agonist peptides. Structural
requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of
agonist function. The Journal of biological chemistry 267, 13146-13149

16.

Vassart, G., Pardo, L., and Costagliola, S. (2004) A molecular dissection of the glycoprotein
hormone receptors. Trends in biochemical sciences 29, 119-126

17.

Paavola, K. J., Stephenson, J. R., Ritter, S. L., Alter, S. P., and Hall, R. A. (2011) The N terminus
of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. The
Journal of biological chemistry 286, 28914-28921

18.

Andersson, H., D'Antona, A. M., Kendall, D. A., Von Heijne, G., and Chin, C. N. (2003)
Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Molecular
pharmacology 64, 570-577

131

19.

Hague, C., Chen, Z., Pupo, A. S., Schulte, N. A., Toews, M. L., and Minneman, K. P. (2004) The
N terminus of the human alpha1D-adrenergic receptor prevents cell surface expression. The
Journal of pharmacology and experimental therapeutics 309, 388-397

20.

Dunham, J. H., Meyer, R. C., Garcia, E. L., and Hall, R. A. (2009) GPR37 surface expression
enhancement via N-terminal truncation or protein-protein interactions. Biochemistry 48, 1028610297

21.

Dohlman, H. G., Thorner, J., Caron, M. G., and Lefkowitz, R. J. (1991) Model systems for the
study of seven-transmembrane-segment receptors. Annual review of biochemistry 60, 653-688

22.

Slessareva, J. E., and Dohlman, H. G. (2006) G protein signaling in yeast: new components, new
connections, new compartments. Science 314, 1412-1413

23.

Mentesana, P. E., and Konopka, J. B. (2001) Mutational analysis of the role of N-glycosylation in
alpha-factor receptor function. Biochemistry 40, 9685-9694

24.

Overton, M. C., and Blumer, K. J. (2002) The extracellular N-terminal domain and
transmembrane domains 1 and 2 mediate oligomerization of a yeast G protein-coupled receptor.
The Journal of biological chemistry 277, 41463-41472

25.

Uddin, M. S., Kim, H., Deyo, A., Naider, F., and Becker, J. M. (2012) Identification of residues
involved in homodimer formation located within a beta-strand region of the N-terminus of a
Yeast G protein-coupled receptor. Journal of receptor and signal transduction research 32, 65-75

26.

Shi, C., Kendall, S. C., Grote, E., Kaminskyj, S., and Loewen, M. C. (2009) N-terminal residues
of the yeast pheromone receptor, Ste2p, mediate mating events independently of G1-arrest
signaling. Journal of cellular biochemistry 107, 630-638

27.

Marsh, L. (1992) Substitutions in the hydrophobic core of the alpha-factor receptor of
Saccharomyces cerevisiae permit response to Saccharomyces kluyveri alpha-factor and to
antagonist. Molecular and cellular biology 12, 3959-3966

132

28.

Son, C. D., Sargsyan, H., Naider, F., and Becker, J. M. (2004) Identification of ligand binding
regions of the Saccharomyces cerevisiae alpha-factor pheromone receptor by photoaffinity crosslinking. Biochemistry 43, 13193-13203

29.

Dohlman, H. G., Goldsmith, P., Spiegel, A. M., and Thorner, J. (1993) Pheromone action
regulates G-protein alpha-subunit myristoylation in the yeast Saccharomyces cerevisiae.
Proceedings of the National Academy of Sciences of the United States of America 90, 9688-9692

30.

Hauser, M., Kauffman, S., Lee, B. K., Naider, F., and Becker, J. M. (2007) The first extracellular
loop of the Saccharomyces cerevisiae G protein-coupled receptor Ste2p undergoes a
conformational change upon ligand binding. The Journal of biological chemistry 282, 1038710397

31.

Turcatti, G., Nemeth, K., Edgerton, M. D., Meseth, U., Talabot, F., Peitsch, M., Knowles, J.,
Vogel, H., and Chollet, A. (1996) Probing the structure and function of the tachykinin
neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific
sites. The Journal of biological chemistry 271, 19991-19998

32.

Ganusova, E. E., Ozolins, L. N., Bhagat, S., Newnam, G. P., Wegrzyn, R. D., Sherman, M. Y.,
and Chernoff, Y. O. (2006) Modulation of prion formation, aggregation, and toxicity by the actin
cytoskeleton in yeast. Molecular and cellular biology 26, 617-629

33.

Sherman, F. (1991) Getting started with yeast. Methods in enzymology 194, 3-21

34.

Reynolds, T. B., and Fink, G. R. (2001) Bakers' yeast, a model for fungal biofilm formation.
Science 291, 878-881

35.

Bajaj, A., Celic, A., Ding, F. X., Naider, F., Becker, J. M., and Dumont, M. E. (2004) A
fluorescent alpha-factor analogue exhibits multiple steps on binding to its G protein coupled
receptor in yeast. Biochemistry 43, 13564-13578

36.

Huang, L. Y., Umanah, G., Hauser, M., Son, C., Arshava, B., Naider, F., and Becker, J. M.
(2008) Unnatural amino acid replacement in a yeast G protein-coupled receptor in its native
environment. Biochemistry 47, 5638-5648
133

37.

Slauch, J. M., Mahan, M. J., and Mekalanos, J. J. (1994) Measurement of transcriptional activity
in pathogenic bacteria recovered directly from infected host tissue. BioTechniques 16, 641-644

38.

Raths, S. K., Naider, F., and Becker, J. M. (1988) Peptide analogues compete with the binding of
alpha-factor to its receptor in Saccharomyces cerevisiae. The Journal of biological chemistry 263,
17333-17341

39.

David, N. E., Gee, M., Andersen, B., Naider, F., Thorner, J., and Stevens, R. C. (1997)
Expression and purification of the Saccharomyces cerevisiae alpha-factor receptor (Ste2p), a 7transmembrane-segment G protein-coupled receptor. The Journal of biological chemistry 272,
15553-15561

40.

Pinson, B., Chevallier, J., and Urban-Grimal, D. (1999) Only one of the charged amino acids
located in membrane-spanning regions is important for the function of the Saccharomyces
cerevisiae uracil permease. The Biochemical journal 339 ( Pt 1), 37-42

41.

Umanah, G. K., Huang, L. Y., Maccarone, J. M., Naider, F., and Becker, J. M. (2011) Changes in
conformation at the cytoplasmic ends of the fifth and sixth transmembrane helices of a yeast G
protein-coupled receptor in response to ligand binding. Biochemistry 50, 6841-6854

42.

Wang, H. X., and Konopka, J. B. (2009) Identification of amino acids at two dimer interface
regions of the alpha-factor receptor (Ste2). Biochemistry 48, 7132-7139

43.

Gehret, A. U., Connelly, S. M., and Dumont, M. E. (2012) Functional and physical interactions
among Saccharomyces cerevisiae alpha-factor receptors. Eukaryotic cell 11, 1276-1288

44.

Jenness, D. D., Li, Y., Tipper, C., and Spatrick, P. (1997) Elimination of defective alpha-factor
pheromone receptors. Molecular and cellular biology 17, 6236-6245

45.

Blumer, K. J., Reneke, J. E., and Thorner, J. (1988) The STE2 gene product is the ligand-binding
component of the alpha-factor receptor of Saccharomyces cerevisiae. The Journal of biological
chemistry 263, 10836-10842

134

46.

Lin, J. C., Duell, K., and Konopka, J. B. (2004) A microdomain formed by the extracellular ends
of the transmembrane domains promotes activation of the G protein-coupled alpha-factor
receptor. Molecular and cellular biology 24, 2041-2051

47.

Akal-Strader, A., Khare, S., Xu, D., Naider, F., and Becker, J. M. (2002) Residues in the first
extracellular loop of a G protein-coupled receptor play a role in signal transduction. The Journal
of biological chemistry 277, 30581-30590

48.

Overton, M. C., Chinault, S. L., and Blumer, K. J. (2003) Oligomerization, biogenesis, and
signaling is promoted by a glycophorin A-like dimerization motif in transmembrane domain 1 of
a yeast G protein-coupled receptor. The Journal of biological chemistry 278, 49369-49377

49.

Harley, C. A., and Tipper, D. J. (1996) The role of charged residues in determining
transmembrane protein insertion orientation in yeast. The Journal of biological chemistry 271,
24625-24633

50.

Sen, M., and Marsh, L. (1994) Noncontiguous domains of the alpha-factor receptor of yeasts
confer ligand specificity. The Journal of biological chemistry 269, 968-973

51.

Trueheart, J., Boeke, J. D., and Fink, G. R. (1987) Two genes required for cell fusion during yeast
conjugation: evidence for a pheromone-induced surface protein. Molecular and cellular biology
7, 2316-2328

52.

Gebhart, D., Bahrami, A. K., and Sil, A. (2006) Identification of a copper-inducible promoter for
use in ectopic expression in the fungal pathogen Histoplasma capsulatum. Eukaryotic cell 5, 935944

53.

Tantry, S., Ding, F. X., Dumont, M., Becker, J. M., and Naider, F. (2010) Binding of fluorinated
phenylalanine alpha-factor analogues to Ste2p: evidence for a cation-pi binding interaction
between a peptide ligand and its cognate G protein-coupled receptor. Biochemistry 49, 5007-5015

54.

Shah, A., and Marsh, L. (1996) Role of Sst2 in modulating G protein-coupled receptor signaling.
Biochemical and biophysical research communications 226, 242-246

135

55.

Adams, M. N., Ramachandran, R., Yau, M. K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., and
Hooper, J. D. (2011) Structure, function and pathophysiology of protease activated receptors.
Pharmacology & therapeutics 130, 248-282

56.

Shi, C., Paige, M. F., Maley, J., and Loewen, M. C. (2009) In vitro characterization of ligandinduced oligomerization of the S. cerevisiae G-protein coupled receptor, Ste2p. Biochimica et
biophysica acta 1790, 1-7

57.

Shi, C., Kaminskyj, S., Caldwell, S., and Loewen, M. C. (2007) A role for a complex between
activated G protein-coupled receptors in yeast cellular mating. Proceedings of the National
Academy of Sciences of the United States of America 104, 5395-5400

58.

Reneke, J. E., Blumer, K. J., Courchesne, W. E., and Thorner, J. (1988) The carboxy-terminal
segment of the yeast alpha-factor receptor is a regulatory domain. Cell 55, 221-234

59.

Konopka, J. B., Jenness, D. D., and Hartwell, L. H. (1988) The C-terminus of the S. cerevisiae
alpha-pheromone receptor mediates an adaptive response to pheromone. Cell 54, 609-620

60.

Yi, T. M., Kitano, H., and Simon, M. I. (2003) A quantitative characterization of the yeast
heterotrimeric G protein cycle. Proceedings of the National Academy of Sciences of the United
States of America 100, 10764-10769

61.

Hao, N., Yildirim, N., Wang, Y., Elston, T. C., and Dohlman, H. G. (2003) Regulators of G
protein signaling and transient activation of signaling: experimental and computational analysis
reveals negative and positive feedback controls on G protein activity. The Journal of biological
chemistry 278, 46506-46515

62.

Bardwell, L. (2005) A walk-through of the yeast mating pheromone response pathway. Peptides
26, 339-350

63.

Dube, P., and Konopka, J. B. (1998) Identification of a polar region in transmembrane domain 6
that regulates the function of the G protein-coupled alpha-factor receptor. Molecular and cellular
biology 18, 7205-7215

136

64.

Mathew, E., Bajaj, A., Connelly, S. M., Sargsyan, H., Ding, F. X., Hajduczok, A. G., Naider, F.,
and Dumont, M. E. (2011) Differential interactions of fluorescent agonists and antagonists with
the yeast G protein coupled receptor Ste2p. Journal of molecular biology 409, 513-528

65.

Toyooka, M., Tujii, T., and Takeda, S. (2009) The N-terminal domain of GPR61, an orphan Gprotein-coupled receptor, is essential for its constitutive activity. Journal of neuroscience
research 87, 1329-1333

137

Chapter 4
Formation of Ste2p dimers by a conserved tyrosine residue in the Nterminus that has multiple contacts with the extracellular loop 1
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Abstract
Ste2p, a Saccharomyces cerevisiae G protein-coupled receptor (GPCR) that responds to the 13
amino acid-peptide, α-factor pheromone, initiates the yeast mating pathway after ligand binding.
This receptor has been used as a model to understand the molecular mechanism of signal
transduction by GPCRs, which play essential roles in signal transduction in eukaryotes. Single
and double cysteine mutants of Ste2p were analyzed by disulfide cross-linking to determine
intramolecular and intermolecular interactions. A conserved tyrosine residue (Y26) in the
extracellular N-terminus was found to be a part of a Ste2p dimer intermolecular interface. Y26mediated dimerization was hindered by mutations at V109 and T114, two residues in the
extracellular loop 1 (ECL1), suggesting an interaction between Y26 and V109 or T114. The
amount of Ste2p dimerization was affected by ligand binding suggesting a conformational
change in the N-terminus of the receptor upon activation. In this study we identified a specific
residue in the N-terminus that is involved in dimerization, found interactions between the Nterminus and ECL1, and suggested that the N-terminus changes conformational upon receptor
activation.
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Introduction
Transmission of extracellular signals across the plasma membrane by receptor-mediated
signaling is one of the most fundamental biological processes. G protein-coupled receptors
(GPCRs) are by far the largest and most versatile signaling molecules on the cell surface that are
involved in communication between the extracellular and intracellular environment of a cell.
These receptors serve as highly versatile membrane sensors responding to a broad range of
signals, including photons, hormones, neurotransmitters, ions and lipids (1-3) and translate them
into cellular response. These receptors play crucial roles in many physiological and
pathophysiological processes (4). Not surprisingly, GPCRs are therapeutic targets for a major
portion of currently used drugs (1,5-8). The pharmacological relevance of these receptors is
firmly established by the fact that approximately 30% of the known drugs on the market are
designed to target GPCRs (9).
The structural hallmark of GPCRs is their seven transmembrane domains connected by
alternating extracellular and intracellular loops. Ligand binding promotes a conformational
change in the receptor that triggers the cellular response via intracellular transducers, the
heterotrimeric (α, ß, γ subunits) guanine (G-) nucleotide binding proteins and/or ß-arrestin (10).
The conformational changes involve the movement of transmembrane domains (11-16).
However, concomitant changes are also expected to occur in other domains of the receptor
including the loop regions and the N- as well the C-termini.
Structurally, a GPCR can be divided into three parts: (i) the extracellular region
consisting of the N-terminus and the three extracellular loops (ECL1-ECL3), (ii) the
transmembrane domains (TM1-TM7), and (iii) the intracellular region consisting of three
intracellular loops (ICL1-ICL3), an intracellular amphipathic helix (H8) that is part of the C140

terminus close to TM7, and the remaining portion of the C-terminus. Although all GPCRs
contain these three distinct regions, the majority of studies have focused on the transmembrane
helices. However, a growing number of studies indicate that the N-terminus also plays an
important role in receptor function (17-20). For example, studies with class B secretin GPCRs
indicate that the N-terminus is the ligand binding domain for these receptors (21). It has been
proposed that binding of the cognate ligand to the N-terminus induces a conformational change
in the receptor’s N-terminus that enables a built-in agonist epitope to dock near the top of
transmembrane domain 6 and this in turn triggers a conformational change in the heptahelical
bundle, thereby initiating the downstream signaling (22). In class C glutamate receptors, the
conserved N-terminal Venus flytrap module in the N-terminus has been reported to regulate
ligand binding and receptor activation (17,19,20,23). The N-termini of protease-activated
receptors (PARs) and glycoprotein hormone receptors (GpHRs) have also been associated with
receptor activation (24,25). The N-terminus of adhesion G protein-coupled receptor GPR56 has
been reported to constrain receptor activity (26). Truncation of the N-terminus of several GPCRs
including CB1 cannabinoid (27), α1D adrenergic (28) and GPR37 (29) has been shown to
enhance cell surface expression.
The Saccharomyces cerevisiae pheromone receptor Ste2p is a GPCR activated upon
binding α factor, a 13-residue peptide, triggering the activation of a cytoplasmic heterotrimeric G
protein in MATa haploid cells (30). Ste2p has been used as a model for understanding structurefunction relationships of GPCRs using the power of yeast genetics and analysis of the yeast
pheromone response pathway. Although Ste2p lacks strong sequence similarity to mammalian
GPCRs, some mammalian GPCRs have been expressed in yeast and are capable of activating the

141

yeast mating pathway (31,32). Ste2p also exhibits signaling when expressed in mammalian cells
(33).
The N-terminus of Ste2p is ~50 amino acids long and contains two glycosylation sites,
neither of which are essential for receptor function (34). The N-terminus was also reported to be
involved in forming a domain for Ste2p dimerization (35,36). Previous studies of the first
extracellular loop using the substituted cysteine accessibility method (SCAM) reported that
several residues (L102C, N105C, S108C, Y111C and T114C) in this loop were inaccessible to
the sulfhydryl reagent (MTSEA-biotin) used to assess accessibility (37). It was also reported that
mutation of these residues to cysteine affected the glycosylation pattern of the receptor. Because
two glycosylation sites of the receptor are located in the N-terminus at N25 and N32 (34) and the
mutations in the ECL1 affected the glycosylation pattern, we hypothesize that the N-terminus
interacts with ECL1. More recently, several residues in the N-terminus including Y26C, were
also found to be inaccessible to MTSEA-biotin and the Y26C mutant also exhibited markedly
increased dimerization (35). This residue is in the consensus sequence of N-glycosylation N-XS/T (where X is any amino acid except Pro). The tyrosine in this position is conserved among the
α-factor receptors in several fungal species (Figure 4.1). This observation stimulated this
investigation into whether ECL1 interacts with N-terminus.
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Materials and Methods
Media, Reagents, Strains, and Plasmids: The Saccharomyces cerevisiae strain LM102 [MATa
ste2 FUS1-lacZ::URA3 bar1 ura3 leu2 his4 trp1 met1] (38) was used for growth arrest, FUS1lacZ gene induction and saturation binding assays, and the protease-deficient strain BJS21
[MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (39) was used for protein
isolation, immunoblot analyses, and disulfide cross-linking studies in order to lower receptor
degradation during analysis. To facilitate disulfide cross-linking, plasmid pBEC2-FXa was
constructed from plasmid pBEC2 containing a Cys-less Ste2p using primers to introduce tandem
Factor Xa protease cleavage sites between residues T78 and P79 in ICL1 (37). The plasmid
pBEC2-FXa containing C-terminal FLAG™ and His-tagged STE2 with a tandem Factor Xa
cleavage site was transformed by the method of Geitz (40). Transformants were selected by
growth on yeast media (41) lacking tryptophan (designated as MLT) to maintain selection for the
plasmid. The cells were cultured in MLT (2% glucose, 1% casamino acids (Research Products
International Corp., IL, USA), 0.17% yeast nitrogen base without ammonium sulfate (Research
Products International Corp., IL, USA), 0.5% ammonium sulfate (Research Products
International Corp., IL, USA), amino acid dropout mix containing (arginine 0.026 g/L,
asparagine 0.058 g/L, Aspartic acid 0.14 g/L, glutamic acid 0.14 g/L, histidine 0.028 g/L,
isoleucine 0.058 g/L, leucine 0.083 g/L, lysine 0.042 g/L, methionine 0.028 g/L, phenylalanine
0.69 g/L, serine 0.52 g/L, threonine 0.28 g/L, tyrosine 0.042 g/L, valine 0.21 g/L, adenine sulfate
0.058 g/L, uracil 0.028 g/L) and grown to mid log phase at 30°C with shaking (200 rpm) for all
assays.
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Growth Arrest Assays
S. cerevisiae strain LM102 expressing Cys-less Ste2p (ICL1-Xa2) and Cys mutants were grown
at 30°C overnight in MLT, harvested, washed three times with water, and resuspended to a final
concentration of 5×106cells/mL (42). Cells (1 mL) were combined with 3.5 mL of agar noble
(1.1%) and poured as a top agar lawn onto a MLT medium agar plate. Filter disks (BD, Franklin
Lakes, NJ) impregnated with α-factor (4, 2, 1, 0.5, and 0.25 µg/disk) were placed on the top agar.
The plates were incubated at 30°C for 24h and then observed for clear halos around the disks.
The experiment was repeated at least three times, and reported values represent the mean of these
tests.
FUS1-lacZ Gene Induction Assay
Cells expressing Cys-less Ste2p (ICL1-Xa2) and Cys mutants were grown at 30ºC in MLT,
harvested, washed three times with fresh medium and resuspended to a final concentration of 5 x
107 cells/mL. Cells (500 µl) were combined with α-factor pheromone (final concentration of
1μM) and incubated at 30ºC for 90 min. The cells were transferred to a 96-well flat bottom plate
(Corning Incorporated, Corning, NY) in triplicate, permeabilized with 0.5% Triton X-100 in 25
mM PIPES buffer (pH 7.2) and then β-galactosidase assays were carried out using fluorescein diβ-galactopyranoside (Molecular Probes, Inc., Eugene, OR) as a substrate as described previously
(43). The reaction mixtures were incubated at 37°C for 60 min and 1.0 M Na2CO3 was added to
stop the reaction. The fluorescence of the samples (excitation of 485 nm and emission of 530
nm) was determined using a 96-well plate reader Synergy2 (BioTek Instruments, Inc., Winooski,
VT). The data were analyzed using Prism software (GraphPad Prism version 6.02 for Windows,
GraphPad Software, San Diego CA). The experiments were repeated at least three times and
reported values represent the mean of these tests.
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Binding Assays
Cells (LM102) expressing different receptor constructs were grown at 30C for ~20 hours at
30C with shaking. Fifty L of cells were reinoculated into fresh medium and grown for ~16
hours to an OD of ~1.8. Cells were washed with 15mM sodium acetate buffer, pH 4.6 containing
sodium azide (10 mM final concentration), resuspended to a final concentration of 5 ×107
cells/ml. Cells were incubated with various concentrations of α-factor for 30 minutes at room
temperature in the dark, washed three times with 15 mM sodium acetate buffer containing
sodium azide (10 mM final concentration), and analyzed on a EMD Millipore (MA, USA) flow
cytometer (Guava 6HT-2L) using excitation at 488 nm and emission at 525. The mean
fluorescence intensity obtained at various concentrations of fluorescent α-factor analogue
[K7(NBD),Nle12] were determined. The samples were protected from light during preincubations and flow cytometry analysis. The mean fluorescence obtained from the Guava was
analyzed by GraphPad Prism using non-linear regression analysis. Because of significant day-today variation in the absolute values of the measured mean fluorescence intensity, all comparisons
between different strains displayed in the figures show assays performed in parallel within the
same experiment.
Immunoblots
Immunoblot analysis of Ste2p was carried out as described previously (44). Cells (BJS21)
expressing various Ste2p constructs grown in MLT were used to prepare total cell membranes as
previously described (37,45). For studies of disulfide cross-linking, membranes were solubilized
in SDS sample buffer (30% glycerol, 3% SDS, 0.01% bromphenol blue, 0.1875 M Tris, pH 6.8)
without 2-mercaptoethanol. Proteins were fractioned by SDS−PAGE (10% acrylamide, 0.1%
SDS was used in the running buffer) along with pre-stained Precision Plus protein standards
145

(BioRad) and transferred to an ImmobilonTMP membrane (Millipore Corp., Bedford, MA).
The blot was probed with anti-FLAG™ M2 antibody (Sigma/Aldrich Chemical, St. Louis,
MO), and bands were visualized with the West Pico chemiluminescent detection system
(Pierce) using ChemiDoc™ XRS+ system (BioRad, Hercules, CA). The intensity of Ste2p
signals was measured by densitometry using Image Lab™ s oftware (version 4.1, BioRad,
Hercules, CA). Multiple repeats of immunoblot experiments yielded similar results.
Constitutively-expressed membrane protein Pma1p was used as a loading control as described
previously (46) using Pma1p antibody (Thermo Scientific, Rockford, IL).
Disulfide Cross-Linking with Cu-Phenanthroline
Disulfide cross-linking was carried out as described previously (44). One hundred µg of
membrane protein preparation was treated with a fresh preparation (pH 7.4) of Cu(II)-1,10phenanthroline (Cu-P; final concentration, 2.5 μM CuSO4 and 7.5 μM phenanthroline). The
reaction was carried out at room temperature for 20 min, terminated with 50 mM EDTA, and
kept on ice for 20 min followed by adding SDS sample buffer without 2-mercaptoethanol. The
membrane preparation was incubated in the absence or presence -factor (1 µM final
concentration) for 30 min prior to Cu-P treatment in experiments performed to examine the
influence of ligand on dimerization.
Factor Xa digestion
The membrane protein preparation (40 μg) was incubated with 0.4 unit of Factor Xa (Novagen)
in Factor Xa cleavage buffer (0.1M NaCl, 50 mM Tris-HCl, 5 mM CaCl2, pH 8.0) containing
0.1% Triton X-100 for 16h at 4C. Each sample was divided into two aliquots. The reactions
were terminated by adding one-third the volume of Laemmli sample buffer (30% glycerol, 3%
SDS, 0.01% bromphenol blue, 0.1875 M Tris, pH 6.8). To one aliquot β-mercaptoethanol (final
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concentration, 1%, v/v) was added for reducing conditions. Samples were analyzed by SDSPAGE and Western blotting as described above.
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Results
Expression and Biological Activities of Cys Mutant Receptors:
To determine intramolecular interaction between the N-terminus (NT) and extracellular
loop 1 (ECL1) of Ste2p, one residue (Y26) in the NT and five residues (N105, S108, V109,
Y111 and T114) in the ECL1 were chosen for mutation to Cys to investigate possible
interactions by assaying for the formation of disulfide linkages. These residues were chosen for
several reasons: (i) Y26 was found to be conserved in the N-terminal domains of α-factor
pheromone receptors of the fungi Saccharomyces cerevisiae, Ashybya gossypii, Candida
albicans, Candida dubliniensis, Candida tropicalis, Debaryomyces hansenii, Eremothecium
cymbalariae, Kluyveromyces lactis, Lachancea kluyveri, Naumovozyma castelllii, Naumovozyma
dairenesis, and Scheffersomyces stipits. The N-terminal regions of the α-factor pheromone
receptors of these fungi were compared by amino acid sequence alignment. TMHMM 2.0 (47)
was used to predict N-terminal regions and Clustal Omega (48) was used for alignment (Figure
4.1). All twelve receptors analyzed in this study were predicted to have an N-terminal domain of
a 45-53 residues. The multiple sequence alignment of the N-terminal domain of these receptors
demonstrated that only two residues, Y26 and F38, in the entire N-terminus were absolutely
conserved, (ii) Y26 was suggested to be solvent inaccessible as determined by the substituted
cysteine accessibility method. and the Y26C mutant demonstrated a greatly increased
dimerization in a previous study (35), (iii) Y26 is located within one of the two known
glycosylation motifs (associated with N25 & N32) of Ste2p (34), (iv) it is located within a
predicted beta strand in the N-terminus (35,49), and (v) mutation of residues N105, S108, V109,
Y111 and T114 to Cys led to changes in the glycosylation pattern of the receptors, although the
glycosylation sites are located in the N-terminus at N25 and N32 (37).
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Figure 4.1. Sequence alignments of yeast pheromone α-factor receptors from different
fungi. The N-terminal regions of S. cerevisiae, Ashybya gossypii, Candida albicans, Candida
dubliniensis, Candida tropicalis, Debaryomyces hansenii, Eremothecium cymbalariae,
Kluyveromyces lactis, Lachancea kluyveri, Naumovozyma castelllii, Naumovozyma dairenesis,
and Scheffersomyces stipits α-factor pheromone receptors were compared by amino acid
sequence alignment. TMHMM 2.0 (47) was used to predict N-terminal regions for
alignment by Clustal Omega (48). Sequence conservation is shown at the bottom of the
aligned sequences. Graphical representation (sequence logo) shows sequence conservation.
To eliminate non-specific cross-linking, the template for the introduction of these
mutations was a Cys-less receptor (37). The Cys-less template also contained two C-terminal
epitope tags (FLAG and 6XHIS) and tandem Factor Xa cleavage sites (IEGRIEGR) in the first
intracellular loop in order to facilitate detection of interdomain cross-linking (Figure 4.2). The
Cys-less Ste2p-FLAG-His receptor (referred to herein as “wild-type”) and the receptor with the
Factor Xa cleavage sites in ICL1 (referred to herein as “ICL1-Xa2”) demonstrated similar
expression levels as well as almost identical biological activities in growth arrest and FUS1-LacZ
assays indicating that incorporating the protease cleavage sites did not alter receptor function
(Figure 4.3).
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Figure 4.2. Diagram of Ste2p showing positions of Cys mutations and modifications
introduced to facilitate disulfide cross-linking and inter- and intra-molecular interactions.
The tandem Factor Xa protease cleavage sites engineered into ICL1 are marked with
“XX”. The FLAG and HIS epitope tags engineered into the C-terminus are also shown.
The two endogenous Cys residues (C59 and C252 – hatched circles) were mutated to Ser to
generate Cys-less Ste2p. The sites of Cys mutation engineered into into the NT and ECL1
regions for disulfide cross-linking (Y26C, N105C, S108C, V109C, Y111C and T114C) are
shown in grey circles. The two known glycosylation sites are shown with “ψ” symbol.
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Figure 4.3. Comparison of the expression levels and signaling activities of the WT and
ICL1-Xa2 receptor used in this study. ICL1-Xa2 is the Cys-less receptor containing the Cterminal FLAG and His epitope tags and a tandem Factor Xa digestion site in IL1. Wildtype is the Cys-less receptor without the Factor Xa digestion site containing the FLAG and
His epitopes. (A) total membranes prepared from the cells expressing wild-type and ICL1Xa2 constructs were immunoblotted using anti-FLAG antibody. The bottom panel shows
the same immunoblot re-probed using antibody against Pma1p, a constitutively expressed
plasma membrane protein used as a loading control. (B) The zone of growth inhibition of
strains carrying the indicated receptors was measured at various concentrations of αfactor. (C) Signaling activities of the constructs determined by pheromone-induced FUS1LacZ activity. The grey bars represent the constitutive signaling and the black bars
represent the α-factor induced signaling activity. The signaling was normalized to that of
the wild-type construct.
The signaling activities of the cysteine mutants were examined by pheromone-induced
growth arrest and FUS1-LacZ induction assays. The growth arrest assay is a sensitive test that is
used to determine the ability of cells expressing Ste2p to maintain pheromone-induced cell
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division arrest over a period of 24h. The FUS1-LacZ induction assay, on the other hand,
measures an early response of the yeast cell to pheromone. The strains used in this study were
engineered with a reporter gene construct consisting of a fusion between FUS1 promoter and the
lacZ gene encoding the enzyme β-galactosidase (50). The FUS1-LacZ assay allows for fast,
sensitive detection of mating pathway activation by assessing the induction of β-galactosidase
activity in response to mating pheromone. The growth arrest activity of the mutants varied from
33-90% of the ICL1-Xa2 control whereas the FUS1-LacZ activity varied from 30-90% of the
ICL1-Xa2 control (Table 4.1). It was noticed that growth arrest activity and FUS1-LacZ activities
of some mutants were different. For example, S108C exhibited 65% growth arrest compared to
the ICL1-Xa2 control and 30% FUS1-LacZ activity. The Y26C/V109C exhibited 34% growth
arrest activity and 72% FUS1-LacZ activity. The difference between the FUS1-LacZ activity and
cell division arrest (growth arrest activity) has been observed in many studies and has been
explained on the basis of the amount of time after pheromone exposure when the response was
measured (51-53).
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Table 4.1. Biological activities of Cys mutant receptors
β-galactosidase activity
Receptor

Growth arrest
activity1

1

Basal

Induced Activity3

Activity2

ICL1-Xa2

1.00

1.00±0.16

1.00±0.05

Y26C

0.60

1.12±0.10

0.53±0.03

N105C

0.79

0.97±0.18

0.43±0.01

Y26C/N105C

0.40

1.04±0.16

0.47±0.04

S108C

0.65

1.01±0.14

0.30±0.02

Y26C/S108C

0.59

0.97±0.21

0.45±0.02

V109C

0.84

0.95±0.12

0.89±0.01

Y26C/V109C

0.34

0.97±0.05

0.72±0.02

Y111C

0.90

0.97±0.04

0.30±0.01

Y26C/Y111C

0.70

0.94±0.04

0.64±0.01

T114C

0.87

1.00±0.04

0.57±0.01

Y26C/T114C

0.75

0.98±0.01

0.39±0.02

Relative halo size was compared to the halo size of the ICL1-Xa2 receptor at 1 µg of α-factor

applied to a disc. The standard deviation of the halo activity for all receptors was within ±0.1
(three replicates).
2

Relative activity (±standard deviation) compared with basal activity of the ICL1-Xa2.

3

Relative activity (±standard deviation) compared with induced activity of the ICL1-Xa2 at 1 µM

of α-factor.
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The expression level of each single and double-Cys mutant receptor was determined by
Western blot analysis. All mutant receptors showed several bands between 44 and 55 kDa
(Figure 4.4A). The multiple bands are typical of Ste2p expression and are due to differences in
the glycosylation state, which does not influence receptor function (34). Although the two
intrinsic Cys residues have been substituted, a weak band at ~110 kDa, corresponding to a
dimerized form of Ste2p, was observed for the ICL1-Xa2 receptor. This band is likely a native,
noncovalent dimer which was not disrupted by membrane protein preparation or SDS-PAGE.
Such dimers have been observed on SDS-PAGE gels in our lab (35,43,44,54) and those of others
working with Ste2p (49,55,56). Although the Cys constructs were expressed as judged by the
Western blot, there was a large variability in the amount of receptor expressed, the glycosylation
pattern, and the distribution of monomer to dimer among these mutants (Figure 4.4A).
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Figure 4.4. (A) Ste2p expression levels of various Cys mutants. Whole cell lysates from cells
expressing various mutants were prepared as described in Materials and Methods. The cell
lysates were run on SDS-PAGE gel under non-reducing conditions; the gel was blotted and
probed using antibody against the C-terminal FLAG epitope tag to detect the presence of
Ste2p at either the monomer or dimer positions, (B) Effect of reducing agent (βmercaptoethanol) on dimerization. Cell lysates prepared from cells were run on SDSPAGE under reducing conditions; the gel was blotted and probed with anti-FLAG
antibody to detect the presence of Ste2p at either the monomer or dimer positions, (C)
Effect of ligand binding on dimerization. Cell lysates were incubated with -factor (1µM
final concentration); the membrane extracts were run on SDS-PAGE gel under nonreducing conditions; the gel was blotted and probed with anti-FLAG antibody to detect the
presence Ste2p at either the monomer or dimer positions. Molecular mass markers (kDa)
are indicated on the left-hand side.

155

156

The N-terminal Cys Mutant Y26C Forms Dimers:
Ste2p is observed on immunoblots predominantly as a monomer of about 50 kDa as most
non-covalent interactions between receptors are disrupted by the conditions of the SDS-PAGE.
However, some SDS-resistant dimers persist as had been observed in many studies
(37,43,44,55,57,58). Consistent with the previous studies, Ste2p was observed predominantly as
a monomer at about 50 Kda with a small amount SDS-resistant dimer at about ~110 kDa in our
Cys-less construct ICL1-Xa2 (Lane ICL1-Xa2, Figure 4.4A). On the other hand, Y26C exhibited
a strong dimer with a small amount of monomer (Lane Y26C, Figure 4.4A). The single Cys
mutants N105C, S108C, V109C, Y111C and T114C showed predominantly as a monomer with a
small amount of dimer. Additionally, with the exception of V109C, Ste2p banding pattern in the
other single Cys mutants was different from the ICL1-Xa2 control as exhibited by diffuse bands
between ~55 and ~70 Kda. The diffuse banding pattern was attributed to changes in the
glycosylation pattern of the receptors as these bands collapsed into a major monomeric band
upon treatment with PNGase (37). The Ste2p expression levels of these mutants were also
weaker than that of the ICL1-Xa2 when the loading control (not shown) is taken into account.
The low expression level of the ECL1 single mutants (N105C, S108C, Y111C, and T114C) was
also observed previously (37). The expression levels of the double Cys mutants were also
weaker than that of the ICL1-Xa2 when the amount of protein loading is considered (Figure
4.4A). The banding pattern of the double Cys mutants was also different from the ICL1-Xa2 as
exhibited by a strong band (at about 50 Kda) along with a small amount of diffused bands
between ~50 and ~70 Kda. Since the diffused banding pattern was not observed in Y26C and
observed in N105C, S108C, Y111C and T114C, the differential banding pattern in the double
Cys mutants can be attributed to mutations in ECL1.
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The majority of the double Cys mutants exhibited stronger dimer with weaker monomer
as compared to those of the ICL1-Xa2 under non-reducing condition (Figure 4.4A). As stated
above, the ICL1-Xa2 and virtually all of the single Cys mutants of Ste2p exhibited no or faint
bands at about 110 kDa consistent with a small amount of dimerized Ste2p. Since strong dimer
was demonstrated in the majority of the double Cys mutants containing Y26C and weak dimer in
the corresponding single Cys mutants, the dimers formed by these mutants can be attributed to
Y26C. The dimer bands at ~110 kDa of the all the double Cys mutants decreased by the addition
of β-mercaptoethanol indicating the involvement of disulfide bonds in stabilization of the dimer
(Compare Figure 4.4A & B; See Table 4.2).
Analysis of the ratio of dimer to monomer in the gels under non-reducing conditions
showed that the dimer/monomer ratio of Y26C was ~28 fold greater than that of the ICL1-Xa2
control, whereas that of the double Cys mutants (Y26C/N105C, Y26C/S108C, Y26C/V109C,
Y26C/Y111C and Y26C/T114C) ranged from about 4- to 8-fold greater (Table 4.2). The dimer
ratio of the single Cys mutants ranged from 2-4 fold greater than that of the ICL1-Xa2 control.
Under reducing conditions, the dimer to monomer ratio of the Y26C and all the double Cys
mutants decreased significantly (p<0.05), whereas the ratio did not change in any of the other
single Cys mutants suggesting that the dimerization in the double Cys mutants were maintained
by Y26C. No significant difference was observed in the ratio of dimer to monomer ratio among
Y26C/N105C, Y26C/S108C and Y26C/Y111C. Also no significant difference in the ratio was
observed between the Y26C/V109C and Y26C/T114C. These results indicate that the
dimerization by Y26C is affected by mutation at positions V109C and T114C, whereas mutation
at other positions did not affect dimerization.
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Table 4.2. Dimer to monomer ratio of Cys mutants in non-reducing and reducing
conditions
Non-reducing1

Reducing2

ICL1-Xa2

1.0

1.0

Y26C*

27.9

12.3

N105C

2.2

2.3

Y26C/N105C*

8.0

5.9

S108C

3.1

2.3

Y26C/S108C*

8.3

4.4

V109C

3.7

2.2

Y26C/V109C*

5.7

3.4

Y111C

4.4

3.2

Y26C/Y111C*

8.2

4.5

T114C

1.9

1.3

Y26C/T114C*

4.1

2.6

Receptor

1

Relative dimer to monomer ratio of the Cys mutants as compared to that of the ICL1-Xa2 in the

absence of -ME.
2

Relative dimer to monomer ratio of the Cys mutants as compared to that of the ICL1-Xa2 in the

presence of -ME.
Significant difference (p<0.05)) in dimer to monomer ratio of the receptors in non-reducing and
reducing conditions is indicated by “*”. The dimer to monomer ratio of the mutants of the all the
mutants was normalized to that of the ICL1-Xa2. The standard deviation of the relative dimer to
monomer ratio for all receptors was within ±0.6.
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Conformational Changes in the N-terminus Upon Ligand Binding: It is generally believed that
activation of GPCRs upon ligand binding results in a conformational change involving
rearrangement of the various receptor domains (59-62). Previous studies have also shown that
binding of -factor affected Ste2p dimer formation (36,44,58). Additionally, the N-terminus of
Ste2p was reported to be involved in dimerization in several studies (35,36). A commonly used
method to examine ligand-induced conformational change in GPCRs is disulfide cross-linking
involving cysteine-substituted mutant receptors. This strategy can be used to determine the
differences in disulfide formation between two receptor monomers containing Cys residues in
the presence and absence of ligand (58,63,64). We investigated whether incubation with -factor
would influence dimerization of the mutants examined in this study. We observed that dimer
formation by the ICL1-Xa2 control and majority of the mutants was not affected by agonist.
However, three mutants (Y26C, Y26C/N105C and Y26C/S108C) exhibited a significant
difference in the ratio of dimer to monomer in the absence or presence of agonist (Compare
Figure 4.4A & C; see Figure 4.5). The dimer to monomer ratio of Y26C significantly decreased
upon incubation with α-factor. On the other hand, the dimer to monomer ratio of Y26C/N105C
and Y26C/S108C increased significantly. These results suggest that -factor binding induces
conformational changes in the N-terminus and EL1 of Ste2p which alters the availability of the
Y26C, Y26C/N105C and Y26C/S108C residues for cross-linking, whereas for the other mutants
of the ECL1 dimerization is not affected by ligand binding. These results indicate that the dimer
interface formed by the N-terminus of the receptor changes upon receptor activation.
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Figure 4.5. Effect of ligand binding on dimerization. Band intensity of dimer and monomer
forms of Ste2p was quantified from Western blots (Figure 4.4A & C) using Image Lab
(version 4.1). The dimer/monomer ratio of the mutants was normalized to that of the ICL1Xa2. Black and grey bars represent the ratio of dimer to monomer in the absence or
presence of -factor, respectively. Statistical significance (p<0.05) in the dimer-monomer
ratio is indicated by an asterisk.
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Determination of intramolecular interaction between N-terminus and extracellular loop 1:
The experiments described above indicated that dimerization mediated by Y26C was hindered by
the V109C and T114C mutations in ECL1 suggesting a possible interaction between Y26C and
these two positions in Ste2p. To test this idea, we took advantage of the protease (Factor Xa)
digestion site engineered into ICL1 of Ste2p. If cross-linking between Y26C and V109C or
T114C occurred, subsequent Factor Xa digestion would yield a full-length receptor, which can
be detected by antibody against the C-terminal FLAG epitope tag (Figure 4.6, right panel). In
contrast, if cross-linking did not occur, the receptor would be cut into two fragments, and a 42
kDa band would be detected on immunoblots using the C-terminal FLAG antibody (Figure 4.6,
left panel). As expected, digestion of ICL1-Xa2 receptor with Factor Xa led to detection of a 42
kDa fragment, and this digestion also lowered the total amount of Ste2p detected in both the
monomer and dimer (non-disulfide) form(compare lanes 1 and 2 in Figure 4.7A) . In contrast, the
42 kDa fragment protease digestion fragment was not detected in Y26C/V109C and
Y26C/T114C mutants (lanes 4 and 6 in Figure 4.7A). Similar results were obtained when the
receptors were incubated without (lanes 1-6) or with α-factor (lanes 7-12) before digestion with
Factor Xa. The monomer bands (~55 kDa) are due to incomplete Factor Xa digestion. We
performed partial digestion because a longer incubation led to degradation of proteins.
To ascertain if the interaction was indeed due to disulfide cross-linking, all of the
receptors showed the 42 kDa band, when treated with a reducing agent (-mercaptoethanol) after
protease digestion in both the presence and absence of α-factor (Figure 4.7B). These results
demonstrate that Y26 in the extracellular N-terminus and V109 and T114 in ECL1 of Ste2p
molecule are in close proximity and provide evidence that the N-terminus and ECL1 may
interact via these contacts.
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Figure 4.6. Diagram showing the schematic of determination of intramolecular interaction
using protease Factor Xa digestions followed by immunoblot detection using antibody
against the C-terminal FLAG epitope tag. Non-reducing and reducing conditions of the
sample buffer is indicated by NR and R respectively. The diagram of immunoblot on the
left shows no interaction and the diagram of the immunoblot on the right shows a positive
interaction. The N and C-termini of Ste2p are indicated by N and C, respectively. The
green in ICL1 indicates the location of the protease Factor Xa cleavage site. The FLAG and
His (6) epitope tags are shown in black.
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Figure 4.7. Factor Xa digestion. Membranes prepared from cells expressing the indicated
receptors were prepared and digested as described in Materials and Methods. The samples
were separated by SDS-PAGE in non-reducing (A) and reducing (B) conditions. The 42
kDa Ste2p fragment detected is marked with an arrow. The molecular markers are shown
on the left.
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Discussion
We herein present data indicating a role for a highly conserved tyrosine residue in the Nterminus of Ste2p in dimerization and interaction with ECL1. Specifically, we identified Tyr26
as a key residue that is important for Ste2p dimerization facilitated by two residues Val109 and
Thr114 in ECL1. Furthermore, using disulfide cross-linking methodology, we provide evidence
that Tyr26 interacts with Val109 or Thr114. We also present data suggesting that the Nterminus-mediated dimer interface of the receptor changes upon receptor activation. The
disulfide cross-linking studies were carried out with Ste2p in its membrane-bound state. The
maximum distance between α-carbons linked by disulfide bonds was shown to be about 7Å (65).
Thus, these experiments should identify amino acid side chains that are within this distance.
Cysteine residues engineered into GPCRs has been applied to facilitate disulfide bond formation
in several GPCRs including Ste2p (44,54,58,61,66-69).
It had been suggested that the N-terminus of Ste2p is involved in dimerization (35,36).
Our results support these findings and furthermore identified a specific residue in the N-terminus
that facilitates Ste2p dimerization. The mutant receptor Y26C showed significantly increased
dimerization over that of the ICL1-Xa2 (Figures 4A, 4B & Table 4.2). The finding that Y26C
participates in dimer formation is in good agreement with the recently published results that
Y26C is inaccessible to the sulfhydryl reagent MTSEA-Biotin (35) since the Y26C-Y26C
interaction might render Y26C inaccessible. The fact that this residue formed a linkage suggests
that the Ste2p-Ste2p interactions involving this region of the N-terminus have significant spatial
restrictions which might make this region relatively rigid. This is consistent with the prediction
that this region of the receptor has a β strand (35,70,71). Thus our mutational analysis defines a
specific residue (Y26C) that appears to be involved in Ste2p dimerization.
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It is interesting that N-terminus-mediated dimerization was hindered by mutations in the
ECL1 of the receptor. This is consistent with the idea that the N-terminus interacts with
extracellular loop 1. It had been shown previously that mutations in ECL1 affected the
glycosylation pattern of the receptor (37), although the glycosylation sites are located in the Nterminus (34). The mutant receptors Y26C, Y26C/N105C, Y26C/S108C, Y26C/V109C,
Y26C/Y111C and Y26C/T114C exhibited markedly increased dimerization over that of the
ICL1-Xa2 (Figures 4A, 4B & Table 4.2). The dimerization of these mutants was reversed by
treatment with β-ME. On the other hand, the single Cys mutants (N105C, S108C, V109C,
Y111C and T114C) exhibited weak dimerization as compared to the mutants containing Y26C
mutation (Figures 4A, 4B & Table 4.2) and no significant decrease in dimerization was observed
when treated with β-ME, indicating that the small amount of dimers formed by these mutants
was due to SDS-resistant association between receptors that is not mediated by disulfide bonds.
Out of the five double Cys mutants tested, two mutants (Y26C/V109C and Y26C/T114C)
exhibited decreased dimerization as compared to the other three (Y26C/N105C, Y26C/S108C
and Y26C/Y111C) indicating that Y26C-mediated dimerization was prevented by mutations at
positions V109C or T114C. These results are consistent with the idea that interaction of Y26C
with either V109C or T114C will hinder Y26C-Y26C interaction thus reducing dimerization. On
the other hand, the other positions (N105C, S108C, Y111C) do not interact with Y26C and thus
Y26C-Y26C interaction is not affected thereby dimerization maintained by Y26C does not
change. These results suggest that Y26C interacts with these two positions. Since Y26C is
located adjacent to a glycosylation site (N25), it is expected that mutations blocking the
interaction might influence the glycosylation pattern. Indeed, it was observed previously that
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mutation in these positions affect the glycosylation pattern (37). Thus these findings suggest that
Y26 interacts with V109 and T114.
It is important to note that reduced dimerization of Y26C/V109C and Y26C/T114C might
result from non-specific effects of mutation rather than interaction between the N-terminus and
ECL1. To ascertain if specific interactions between Y26C and the two residues in ECL1 existed,
we used disulfide cross-linking followed by Factor Xa digestion. We found that these two
residues (V109C and T114C) in EL1 indeed cross-link with Y26C (Figure 4.8). This strategy has
been used previously in our lab to determine the involvement of TM regions in dimerization
(44).These results support previous studies in which mutation T114C along with N105C, S108C,
and Y111C was found to change glycosylation pattern of the receptor. Our study identified the
specific residues in EL1 and N-terminus that interact with each other. This finding led us to
believe that the N-terminus and EL1 are in close proximity and these two domains have strong
interactions that might play an important role in negative regulation of signaling as discussed in
chapter 3 of this dissertation.
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Figure 4.8. Ste2p dimer mediated by Y26 and its interaction with ECL1. Two Ste2p
molecules (orange and green) are shown with the positions of Y26 (green and orange dots),
V109 (black) and T114 (black). Intramolecular and intermolecular interactions are shown
on the left and right panels, respectively.

The finding that NT is involved in Ste2p dimerization led us to propose that at least four
dimerization interfaces can exist in Ste2p. In addition to the TM1, TM4, TM7 interfaces
previously found (36,44,58), our data suggest that NT-NT interactions are also involved in direct
contacts in the Ste2p dimer. The results described in this study show that cysteine residue
introduced in the N-terminus (NT) forms a disulfide bond with its counterpart in another Ste2p
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monomer (Figure 4.8). Since Y26C-mediated dimerization is prevented by Cys mutations at
V109 and T114, these two residues in ECL1 are in close proximity to Y26C in the receptor.
These results also suggest that the distance between Y26C and V109C or T114C is closer than
that of Y26C of another Ste2p molecule in a Ste2p dimer mediated by Y26C-Y26C interaction
because introduction of Cys at these positions competes out Y26C-Y26C interaction. It is also
possible that Y26C-mediated dimerization was prevented by intermolecular interaction between
Y26C of one Ste2p molecule with V109C or T114C of a second Ste2p molecule.
We also report here that the N-terminus of Ste2p is a dimer interface that changes upon
receptor activation. Specifically, dimerization of Y26C, Y26C/N105C, and Y26C/S108C was
found to change in the presence of α-factor. The dimerization mediated by Y26C was found to
decrease in the presence of α-factor indicating that the dimer interface at the N-terminus of the
receptor moves away from each other during receptor activation. The movement of the Nterminus may affect other domains of the receptor including ECL1 and TM domains which are
believed to be involved in receptor activation. On the other hand, the dimerization mediated by
Y26C/N105C and Y26C/S108C mutants was found to increase suggesting that the dimer
interface mediated by Y26C moves closer to each other. Previous studies in our lab demonstrated
that solvent accessibility of several residues (Y101, Y106, and A112) in ECL1 changes upon
incubation with α-factor thereby indicating the involvement of this region in receptor activation
(37). A 310 helix was also predicted between residues 106-114 in the ECL1.Our results suggest
that Y26 interacts with two residues (V109 and T114) in this region that are part of the 310 helix.
It is possible that in the presence of α-factor, the N-terminus moves away due to conformational
changes in the ECL1 thereby affecting Y26-mediated dimerization. On the other hand, N105 and
S108 are adjacent to these interacting residues in ECL1 (V109 and T114). Thus changes in these
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two residues (N105 and S108) may influence the conformation of the ECL1 thereby affecting
dimerization of Y26C/N105C and Y26C/S108C receptors, resulting in increased dimer
formation due to bring the Y26 closer to each other.
GPCRs have been believed to exist and function as monomers for many years.
Nevertheless, a growing number of studies demonstrated that GPCRs form dimers or higherordered oligomers, which have been proposed to be essential for modulation of receptor function
(1,63,72-77). In most receptors, the transmembrane domains were reported to be involved in
receptor dimerization/oligomerization. However, several studies demonstrated the extracellular
N-terminal domain of Ste2p is also associated with dimerization (35,36). The residue identified
in this study, Y26C, is highly conserved in fungal GPCRs. Conserved residues are often
important for structure and function of proteins and conservation is stronger at protein-protein
interfaces compared to elsewhere on the protein surface (78-81). Thus analysis of sequence
conservation in a protein family is a useful strategy to identify key residues that are important for
protein function (82-91). Protein-protein interaction sites are subjected to substantial selective
pressure to maintain critical interactions throughout the course of evolution (92,93).
These findings provide valuable information relating to the arrangement of the receptor in which
the N-terminus appear to face each other. In the absence of a crystal structure for Ste2p, the
disulfide cross-linking results contributes to understanding structural features of the functional
receptor such as inter-amino terminal interactions that may be involved in oligomerization.
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Conclusions, summary and future studies
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Summary
This dissertation describes the identification of a discrete structure that is involved in
homodimer formation of Ste2p, the yeast α-factor receptor, a model system for mammalian
GPCR peptide hormone receptors. The Substituted Cysteine Accessibility Method (SCAM) was
used to determine the accessibility of residues in the N-terminus and disulfide cross-linking was
used to determine dimer formation by these residues. These studies revealed that certain residues
in the extracellular N-terminus were solvent inaccessible and that these residues also promote
increased dimers formation. The pattern of accessibility combined with the disulfide crosslinking results suggested the presence of a β-strand structure in the N-terminus which was
predicted previously by bioinformatics analysis of this region. Deletion mutagenesis revealed
that the N-terminus is involved in negative regulation of signaling. Further analysis of the Nterminus revealed that a conserved tyrosine residue in the βstrand plays a critical role in receptor
dimerization and likely interacts with two residues (V109 and T114) in ECL1 of the receptor.
Furthermore, the Ste2p dimer interface was found to change upon receptor activation thereby
supporting the emerging idea that dimerization plays an important role in receptor function.
The Substituted Cysteine Accessibility Method (SCAM) was used to determine the
accessibility of residues in the N-terminus and disulfide cross-linking was used to determine if
the N-terminus is part of a dimer interface for Ste2p. The results of these assays indicate that
certain residues in a short segment of the N-terminus of Ste2p do not react with a water-soluble
biotinylation reagent and appeared to be involved in receptor dimerization. Interestingly, the
pattern of solvent accessibility was found to be consistent with a β-sheet-like structure involving
the stretch of residues G20-Y30. It was also found that the dimer interface changed in response
to pheromone indicating a change in conformation of the N-terminus upon receptor activation.
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These findings suggest that the N-terminus of Ste2p possesses a discrete structural domain that
appears to participate in the signaling mechanism. Interestingly, a β-strand was predicted in this
region by sequence analysis (1,2).
Deletion mutagenesis demonstrated that the N-terminus constrains Ste2p signaling activity.
The N-terminus of GPR56, an adhesion GPCR, has also been reported to constrain receptor
activation (3). Previous studies with Ste2p demonstrated a role of the N-terminus in dimerization
(4-6), mating (1,2) and as a site of glycosylation domains(7). Our studies revealed a previously
unrecognized role of the N-terminus: the constraint of signaling activities by stabilizing the
inactive state of the receptor. The proposed interaction between the N-terminus and other
domain(s) of the receptor may function to stabilize the inactive state of the receptor. Thus,
removal of portions of the N-terminal domain may affect Ste2p dimerization or interaction with
other domain(s) of the receptor that is important for activation (4,5). In fact, the β-sheet like
contacts found in the N-terminus may help to maintain the receptor in its inactive conformation
and removal of these residues would thereby facilitate transition to an activated state upon ligand
binding. Previous studies indicated a possible interaction between the N-terminus with the
extracellular loop one (ECL1), based on changes in glycosylation pattern of the receptor which
were observed upon mutation of residues in ECL1, although glycosylation sites are located in the
N-terminus (8).
An evolutionarily conserved tyrosine residue, Y26, in the N-terminus was found to play key
role in receptor dimerization. Two residues in the ECL1 (V109 and T114) facilitate Y26mediated dimerization. The disulfide cross-linking studies indicated that Tyr26 interacted with
Val109 or Thr114. The dimer interface of the receptor was found to change in response to
pheromone indicating a role for dimerization mediated by the N-terminus in receptor activation.
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Because the maximum distance between α-carbons linked by disulfide bonds is about 7Å (9), the
amino acid side chains identified using this methodshould be very close (within 7Å). This
strategy has been used to identify interacting residues in several GPCRs including Ste2p (10-17).

Future studies
Despite the remarkable progress made in the structural biology of GPCRs, a clear
understanding of the extracellular N-terminus and its significance in signal transduction remains
ambiguous. In addition, although dimerization is a widely observed phenomenon in GPCRs, the
functional significance of this phenomenon for the vast majority of GPCRs is still debated. The
results obtained during the course of the studies for this dissertation will aid in understanding the
role of the N-terminus and dimerization in GPCR signal transduction. However, in order to fully
understand the role of this extracellular domain and dimerization in receptor function, further
studies are necessary. A few suggestions are outlined below to elucidate the role of the Ste2p Nterminus and dimerization.
The results obtained in Chapter 2 indicate that SCAM was useful in determining the
accessibility of residues in the extracellular N-terminus. Although these experiments revealed the
accessibility of residues in the inactive state of the receptor, it is not known whether the
accessibility of these residues is changed upon receptor activation. This information is important
since conformational changes also occur in the N-terminus upon receptor activation as indicated
by changes in dimerization in the absence and presence of α-factor, Therefore, SCAM studies of
the residues in the presence of α-factor will provide information regarding conformational
changes in the N-terminus that leads to receptor activation.
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The results described in Chapter 3 of this dissertation indicate that removal of the Nterminus affects signaling and surface expression. However, no specific residue(s) in the Nterminus was identified as being most responsible for this effect. Alanine scanning mutagenesis
in this region might reveal the specific residue(s) responsible for signaling and/or surface
expression. Furthermore, the N-terminus was suggested to be involved in negative regulation but
the mechanism of the regulation is still unknown. The N-terminus possesses two glycosylation
sites located at N25 and N32. A previous report indicated that mutation of these two
glycosylation sites to glutamine did not influence receptor function. However, our studies with
Cys mutation in the glycosylation sites indicate that signaling activity was altered. Thus it
appears that glycosylation in the Ste2p affects signaling but a thorough investigation of the role
of this post-translational modification on receptor function is warranted. For example, three
forms of receptor mutants having none, one or two glycosylation sites can be tested for
functional properties to determine if glycosylation plays a role in receptor function.
Disulfide cross-linking studies demonstrated that a conserved tyrosine residue (Y26) in the
N-terminus interacts with V109 or T114 in ECL1. However, these experiments were carried out
using membranes prepared from cells expressing these receptors. Thus it is not known if the
interaction also occurs in whole cells. Therefore, cross-linking studies using whole cells can be
done to determine the interaction in vivo. The Y26C mutant functions as a major dimer interface
for Ste2p, and exists as a dimer even in the absence of pheromone. The Y26C mutant exhibited
weaker growth arrest activity compared to that of the wild type. On the other hand, Y26A mutant
does not form promote dimerization, but exhibits increased signaling activity suggesting that
dimerization prevents signaling. Although the growth arrest activity of the Y26C and Y26A
mutants was similar, FUS1-LacZ activities of the Y26A mutant was higher indicating that signal
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transduction by dimer and monomer is different. Conformational changes in the receptor
resulting from the activation of a Ste2p dimer may be different from that of the monomer thereby
initiating a signal. SCAM and disulfide cross-linking can be used to understand the
conformational changes which occur in the dimerized receptor in response to pheromone.
Identification of the residues and domains that are involved in GPCR dimerization might
establish the foundation for the design of drugs that specifically affect the signaling crosstalk
between the components of the receptor dimer/oligomer.
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